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Candida species are commonly seen fungi that exist as an element of normal flora in the skin, 
gastrointestinal tract and reproductive tract of humans. Among Candida species, Candida 
albicans is the most common infectious agent but the non-albicans Candida species are 
emerging as pathogens and also colonize human mucocutaneous surfaces. Fungal infections are 
generally opportunistic so the pathogenesis and prognosis of candidial infections are affected by 
the host immune status and also differ greatly according to disease presentations. 
Over the last decade, fungal infections and range of yeasts associated with human infections 
have increased, especially with Candida. Candidiasis has emerged as an alarming opportunistic 
infection with an increase in a number of patients who are immunocompromised, diabetics and 
the elderly. Extensive and prolonged use of antibacterial and cancer chemotherapeutic agents has 
further complicated the situation. 
Mucocutaneous candidiasis can be divided into nongenital disease and genitourinary disease. 
Among nongenitourinary candidiasis, oropharyngeal manifestations are the most common and 
usually are diagnosed in immunocompromised patients, such as human immunodeficiency virus 
(HIV) infected persons . The most frequent manifestations of genitourinary candidiasis include 
Vulvovaginal candidiasis (VVC) in women, balanitis and balanoposthitis in men and Candiduria 
in both sexes. These diseases are remarkably common but occur in different populations, 
immunocompetent as well as immunocompromised. While VVC affects mostly healthy women, 
candiduria is commonly diagnosed in immunocompromised patients or neonates.  
VVC is the second most common after bacterial vaginosis among the many causes of vaginitis 
and it is estimated that approximately 75% of all women suffer at least once in their lifetime 
from vulvovaginal candidiasis (VVC), with 40–50% experiencing at least one additional episode 
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of infection. A small percentage of women (5–8%) suffer from atleast four recurrent VVC per 
year. The prevalence of Candida infections accounts for about 47.5% among diabetic women. 
In contrast to genital manifestations of candidiasis, candiduria is usually diagnosed in elderly 
hospitalized patients and Candida is the most frequently isolated pathogen in nosocomial urinary 
tract infections (UTIs). Candiduria most likely reflects colonization or infection of the lower 
urinary tract or the collecting systems of the kidneys but in some cases, it is a marker for 
hematogenous seeding in the kidney. 
 Candida colonization of the urinary tract is common in patients with Diabetes mellitus. In 
patients receiving broad-spectrum antibiotics or immunosuppressants or those with long-term 
urinary catheters, the clinical course of fungal urinary tract infection (UTI) vary from being an 
asymptomatic and self-limiting disorder to fungal septicemia, which can be fatal. Candida 
albicans has been the fungi most commonly isolated from urine, accounting for 50%–70% of 
isolates in various studies. Candida glabrata and Candida tropicalis are the next most common 
species found in cultures of urine.   
Diabetes mellitus is a chronic, insidious disease that can affect any organ or system of the body 
and one of the major complications associated with it is infection. Although the prevalence of 
infection among diabetic and non-diabetic subjects is similar, the intensity of infection is being 
more severe and the response to therapy slow in diabetic patients. In patients suffering with 
Diabetes mellitus, excess glucose level in the bloodstream can cause several infectious diseases 
ranging from superficial candidiasis to deep seated mycoses. Candidarely on simple carbon 
compounds such as glucose, sucrose, maltose and lactose for their rapid growth and these simple 
sugars increase the fungal population density. Fungal load or count is an important parameter of 
antifungal susceptibility. 
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Candida albicans and related species in the recent times have developed resistance to 
anti‑ fungal agents, in particular to the azole compounds. Hence, accurate species identification 
is important for the treatment of Candida infections, as the non-albicans Candida continue to be 
increasingly documented. 
A number of antifungal agents especially azoles are used to treat candidiasis. Currently, 
Fluconazole is recommended in various guidelines as the first drug of choice because it is less 
toxic and can be taken as a single oral dose. Emergence of Fluconazole-resistant Candida species 
has been progressively reported in the last few years. Several major mechanisms leading to azole 
resistance have been elucidated. Declined effective drug concentrations can be achieved by 
overexpression of a drug’s molecular target, which gives rise to drug resistance. Changes in 
sterol 14α-demethylase (ERG11), the target of azole antifungals, are associated with azole 
resistance in C. albicans . The azole activity is directed against lanosterol 14-α-demethylase 
(Erg11p), which is involved in the biosynthesis of ergosterol.  
Erg11p is a cytochrome P450 enzyme from family 51 (CYP51) encoded by the ERG11 gene . 
This enzyme converts lanosterol to ergosterol, which catalyses the oxidative removal of the 14α-
methyl group from lanosterol. The sterol 14-α-demethylase contains a heme moiety in its active 
site. The unhindered nitrogen of the azoles binds to the heme iron of Erg11p, thus, inhibiting 
enzymatic reaction. In addition, second nitrogen in the azoles has the potential to interact directly 
with the apoprotein of lanosterol-demethylase. The inhibition of Erg11p leads to the 
accumulation of 14α-methylated sterols, thereby blocking the biosynthesis of ergosterol and 
leading to defects in membrane and cellular integrity as ergosterol is an essential component of 
the fungal plasma membrane.  
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 Over-expression of ERG11 gene results in production of a large amount of lanosterol 14α-
demethylase and this favours continuous synthesis of ergosterol and maintenance of the integrity 
of the cell wall which enables Candida to resist Fluconazole . This type of resistance has been 
associated with widespread and continuous usage of Fluconazole as prophylaxis.  
Therefore, the present study was carried out to determine the relative contribution of Candida 
abicans and non-albicans species in diabetic patients with suspected candidiasis , their antifungal 
susceptibility profile and role of ERG11 overexpression in  azole resistance. 
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2.1 Diabetes mellitus: 
Diabetes mellitus is a chronic disease caused by inherited and/or acquired deficiency in 
production of insulin by the pancreas or by the ineffectiveness of the insulin produced. Such a 
deficiency results in increased concentrations of glucose in the blood, which in turn damage 
many of the body's systems, in particular the blood vessels and nerves. 
There are two principle forms of diabetes: 
Type 1 diabetes is formerly known as insulin-dependent diabetes in which the pancreas fails to 
produce the insulin which is essential for survival. This form develops most frequently in 
children and adolescents, but is being increasingly noted later in life. 
Type 2 diabetes is formerly named non-insulin-dependent diabetes in which results from the 
body's inability to respond properly to the action of insulin produced by the pancreas. Type 2 
diabetes is much more common and accounts for around 90% of all diabetes cases worldwide. 
It occurs most frequently in adults. 
Certain genetic markers have been shown to increase the risk of developing Type 1 diabetes. 
Type 2 diabetes is strongly familial, but it is only recently that some genes have been 
consistently associated with increased risk for Type 2 diabetes in certain populations. Both 
types of diabetes are complex diseases caused by mutations in more than one gene, as well as 
by environmental factors. 
Symptoms: 
The symptoms of diabetes may be pronounced, subdued, or even absent. Type 1 diabetes, the 
classic symptoms are excessive secretion of urine (polyuria), thirst (polydipsia), weight loss 
and tiredness. 
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These symptoms may be less marked in Type 2 diabetes. In this form, it can also happen that 
no early symptoms appear and the disease is only diagnosed several years after its onset, 
when complications are already present. 
Prevalence: 
Recently compiled data show that approximately 150 million people have diabetes mellitus 
worldwide and that this number may well double by the year 2025. Much of this increase will 
occur in developing countries and will be due to population growth, ageing, unhealthy diets, 
obesity and sedentary lifestyles. 
By 2025, while most people with diabetes in developed countries will be aged 65 years or 
more, in developing countries most will be in the 45-64 year age bracket and affected in their 
most productive years. 
2.1.1 Diabetes Mellitus and Infections: 
The incidence of infections is increased in patients with diabetes mellitus. Some of these 
infections are also more likely to have a complicated course in diabetics than in nondiabetic 
patients. Diabetic ketoacidosis is precipitated or complicated by an infection in 75% of the 
cases. The mortality rate of patients with an infection and ketoacidosis is 43%. The question 
then arises as to which pathogenic mechanisms are responsible for this high infection rate in 
patients with DM. Possible causes include defects in immunity, an increased adherence of 
microorganisms to diabetic cells, the presence of micro- and macroangiopathy or neuropathy 
and the high number of medical interventions in this group of patients. 
The immune system can be divided into the innate and adaptive-humoral or cellular immune 
systems. Concerning the humoral adaptive immunity, serum antibody concentrations in 
patients with DM are normal. Concerning the adaptive cellular immunity, inhibition of the 
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proliferative response to different stimuli has been observed in the lymphocytes of diabetics 
with poorly controlled disease. Differences in innate immunity between diabetic and non-
diabetic patients and in adherence of microorganisms to diabetic and non-diabetic cells are 
more important in the pathogenesis of the increased prevalence of infections in these patients. 
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2.1.2 Defects in Innate Immunity 
 Complement Function: 
Vergani et al found that 26% of DM type 1 patients had a serum complement factor 4 
concentration (C4) below the normal range. The low C4 values did not appear to be the result of 
consumption. Since nondiabetic identical twins also had a C4 concentration below normal, and 
the genes encoding C4 are linked with the antigens DR3 and DR4 (which are expressed in 95% 
of the Caucasian diabetic patients in contrast to 40% of the general population), it suggests that 
this reduced C4 may be an inherited phenomenon. However an isolated C4 deficiency is not a 
known risk factor for infections in nondiabetic patients and therefore seems not to play an 
important role in the increased risk of infections in patients with DM. 
Cytokines: 
Geerlings et al and Peleg et al studies showed that mononuclear cells and monocytes of persons 
with DM secrete less interleukin-1 (IL-1) and IL-6 in response to stimulation by 
lipopolysaccharides. It appears that the low production of interleukins is a consequence of an 
intrinsic defect in the cells of individuals with DM. However, some studies reported that the 
increased glycation could inhibit the production of IL-10 by myeloid cells, as well as that of 
interferon gamma (IFN-γ) and tumor necrosis factor (TNF)-α by T cells. Glycation would also 
reduce the expression of class I major histocompatibility complex (MHC) on the surface of 
myeloid cells, impairing cell immunity (Price et al) 
Hyperglycemia/Glucosuria: 
Hostetter et al studied the enhancing effect of hyperglycemic environment on the virulence of 
certain microorganisms. An example is Candida albicans, which expresses a surface protein that 
has great homology with the receptor for complement factor 3b (CR3). Normally, opsonization 
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of microorganisms takes place by attachment of complement factor 3b (C3b). Receptors on 
phagocytizing cells recognize this bound C3b and attach, thereby initiating ingestion and killing. 
In a hyperglycemic environment, the expression of the receptor-like protein of C. albicans is 
increased, which results in competitive binding and inhibition of the complement-mediated 
phagocytosis 
Glucosuria found in poorly regulated patients enhances  growth of different  Escherichia 
coli strains, which probably plays a role in the increased incidence of urinary tract infections in 
diabetic patients. So an optimal diabetes regulation can decrease the virulence of some 
pathogenic microorganisms (Geerlings et al). 
2.1.3 Cellular Immunity 
Chemotaxis: 
Mowat et al study showed a significantly lower chemotaxis in PMNs of diabetic patients (type 1 
and type 2) than in those of controls. Study by Delamaire et al showed that the chemotactic 
responses of the PMNs did not alter after the incubation of either glucose or insulin, but returned 
to normal values after the incubation with glucose and insulin together. Since most PMN 
functions are energy-dependent processes, an adequate energy production is necessary for an 
optimal PMN function. Glucose needs insulin to enter the PMNs to generate this energy, which 
may explain the improvement of the chemotactic response after the addition of these two 
substances. 
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Phagocytosis: 
Tater et al and Delamaire et al studies demonstrated that the PMNs of diabetic patients have 
same and a lower phagocytotic capacity compared to PMNs of controls respectively. A study by 
Balasoiu et al showed that the mean HbA1c concentration was lower in patients without 
impaired phagocytosis than in those with impaired phagocytosis. Marhoffer et al showed an 
inverse relationship between the HbA1c levels and the phagocytotic rate. Another study by Gin 
et al showed that the decreased phagocytosis improved, but did not become normal after 36 h of 
normoglycemia. Therefore, it seems that impairment of phagocytosis is found in PMNs isolated 
from poorly regulated patients and that better regulation of the DM leads to an improved 
phagocytotic function 
Oxidative Burst: 
Shah et al used Chemiluminescece (CL) to evaluate the oxidative potential of PMNs, a process 
during which free radicals are synthesized early in the phagocytotic process. CL correlates well 
with antimicrobial activity and may be used as a measure of phagocytotic capacity. Compared to 
controls, CL at baseline was the same in PMNs of diabetic patients. Studies showed after 
stimulation, the CL of diabetic PMNs was lower than that of control PMNs.  
Killing by PMNs: 
The killing capacity of diabetic PMNs is lower than that of control PMNs. An impaired killing 
function of diabetic PMNs was found in studies by Tater et al and Tan et al with Staphylococcus 
aureus as the microorganism, but not in the stugy by Balasoiu et al in which the killing 
of Candida albicans was used as the measure. No correlation was found with glycemic level, 
although some studies have shown that bactericidal activity improved, but did not normalize 
after achieving normoglycemia.(Gin et al) 
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Monocytes And Macrophages: 
Both impaired chemotaxis and phagocytosis of the monocytes of diabetic patients have been 
described by Deresinski et al and Katz et al. In combination with the earlier mentioned decreased 
production of pro-inflammatory cytokines after LPS stimulation in DM type 1 patients, it shows 
that monocyte/macrophage functions are impaired in DM type 1 patients. 
Adherence 
Adherence of a microorganism to mucosal or epithelial cells is an important step in the 
pathogenesis of infections. Host-related factors may influence this adherence. Schaeffer et al 
demonstrated that women with recurrent urinary tract infections have a greater adherence of 
E.coli   to their vaginal and buccal cells compared to controls 
C. albicans infection is frequently found in diabetic patients. Since infection mostly is preceded 
by colonization Aly et al. investigated which risk factors increased the risk of Candida carriage 
in diabetic patients. Risk factors for oral Candida carriage in patients with DM type 1 were a 
lower age and a higher HbA1c level (poor regulation of DM). Continuous wearing of dentures 
and the presence of glucosuria (also an indication of a poor DM regulation) increased the risk 
of Candida carriage in DM type 2 patients, the mean number of cigarettes smoked per day was 
correlated with Candida carriage in DM type 1 and type 2 grouped together. 
 Cameron et al study showed that the carbohydrate composition of receptors probably plays an 
important role in the susceptibility to infections. These receptor changes possibly lead to an 
increased adherence of microorganisms and play a role in the high prevalence of Gram-negative 
bacterial colonization in the respiratory tract of these patients. This mechanism of increased 
adherence, due to an altered receptor carbohydrate composition, is possibly also present in 
diabetic patients.  
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2.1.4 Major Infections Associated With Diabetes Mellitus 
 Bacterial Infections: 
1. Respiratory infections  
2. Tuberculosis  
3. Urinary tract infections 
4. Bacterial pyelonephritis 
5. Emphysematous pyelonephritis  
6. Emphysematous cystitis 
7. Perinephric abscess 
8. Emphysematous cholecystits  
9. Skin and soft tissue infection – Furunculosis, Folliculitis and Subcutaneous abscess 
10. Foot infections 
11. Necrotizing fasciitis 
12. Fournier gangrene 
13. Invasive external otitis 
14. Periodontits  
 Fungal Infections 
 Fungal cystitis 
 Mucocutaneous candidiasis 
 Rhinocerebral mucormycosis 
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2.2 Candida 
2.2.1 Discovery 
The perception of Candida has evolved from the presence of an exudate in the human host to a 
known infectious agent. 200 years of medical history was recorded before the etiological agent 
of oral thrush, the first form of candidiasis described, was correctly identified as a fungal 
pathogen. “Thrush” appears as whitish plagues within the oropharynx or the buccal mucosa or 
tongue.  
One of the main points of contention when defining thrush was whether it originated from the 
host or was an infectious agent, or a combination of the two. The earliest reports of thrush 
predated the concept of a microbial pathogen. In “Of the Epidemics,” Hippocrates described oral 
candidiasis (around 400 B.C.) as “mouths affected with aphthous ulcerations”. In 1665, Pepys 
Diary reported “a patient hath a fever, a thrush and a hiccup” perpetuating the idea that oral 
thrush originates from the host.  
In 1771, Rosen von Rosenstein defined an invasive form of thrush. In 1839, Langenbeck was 
credited with first recognizing a fungus in a patient with typhoid fever. Oropharyngeal and 
esophageal thrush with pseudomembranes were found at autopsy. “Under the microscope 
magnified, the pseudomembranes consisted of an immense number of fungi” .He described in 
detail what is now referred to as septate hyphae, branched pseudohyphae and blastoconidia 
However, he ascribed the entity to the typhoid bacterium rather than the fungus. In 1844, J.H. 
Bennett observed a similar fungus in the sputum and the lungs of a patient with a pneumothorax 
and criticized the conclusion by Lagenbach. The morphologic description of Bennett was 
essentially that as described by Langenbeck. Two years later, Berg explicitly concluded that 
thrush was caused by a fungus and found that spread could occur from communal feeding 
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bottles. Most importantly, he also stated “descriptions of the disease unsupported by 
demonstration of the fungus could not substantiate the diagnosis”. He was able to reproduce the 
infection in healthy children and thereby confirmed his hypothesis that the fungus caused the 
infection . After this discovery, other infections would be ascribed to this dimorphic fungus 
including vaginitis and gastrointestinal candidiasis.  
2.2.2 Nomenclature 
Once the etiology was conclusively demonstrated by mycologists, the next point of contention 
was the identity of the pathogen. While Langenbeck (1839) first documented the fungus 
associated with thrush, he failed to make the direct connection. In 1847, the distinguished French 
mycologist, Charles Philippe Robin, classified the fungus as Oidium albicans using albicans (“to 
whiten”) to name the fungus causing thrush. Hill and later Martin and Jones misclassified 
Candida into the genus Monilia, a genus containing fungi that commonly grow in plants. 
Subsequently, clinicians erroneously referred to the etiology of thrush as “Monilias” despite the 
fact mycologists had already elucidated the morphological differences between the fungus 
associated with thrush and the fungus in the genus Monilia. 
 Christine Berkhout and others noted these differences, particularly the ability of this fungus to 
infect humans. Berkhout reclassified it under the current genus Candida (1923). Candida is 
derived from Latin where toga candida was a white robe worn by Roman Senators. However, it 
was not until 1954 that the Eighth Botanical Congress officially endorsed the binomial Candida 
albicans as the nomen conservandum formally ending the 200 year long uncertainty over the 
etiology and taxonomy of Candida. Currently, there are some 200 organism species within the 
genus Candida.  
16 
 
2.2.3 Morphology 
These yeast-like cells are anamorphic (sexual imperfect) fungi belonging to the class 
Blastomycetes. They are characterized by their polymorphic nature and ability to produce 
budding yeast cells (blastoconodia), mycelia, pseudomycelia and blastospores . Of the nearly 200 
species, only few species are considered to be significant pathogens associated with various 
infections in human - Candida albicans , Candida glabrata ,Candida tropicalis, Candida 
parapsilosis, Candida krusei ,Candida auris, Candida kefyr, Candida dubliniensis, Candida 
guilliermondii, Candida rugosa, Candida haemulonii, Candida viswanathii and Candida 
lusitaniae. 
Out of these, six species- C. albicans, C. glabrata, C. tropicalis, C. parapsilosis Candida 
dubliniensis and Candida krusei are the most commonly associated with human infection. 
Candida is a yeast like fungus that primarily exists and propagates through blastospore 
phenotype (also called blastoconidia). Blastospores are characterized by their oval-shapes, mono-
nucleated cells and propagation through cellular budding. Upon perception of environmental 
signals, C. albicans is able to transform into one of two filamentous forms: psuedohyphae and 
hyphae. Elongated, ellipsoidal cells that are attached to one another are referred to as 
psuedohyphae, while cells that are considered to be true hyphae are characterized by a 
cylindrical cellular morphology and are separated by perpendicular septal walls. These hyphal 
forms are comprised of conjoined cells that are divided by septal walls and are not syncytial in 
composition. 
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C. albicans has evolved into a commensal organism as well as an opportunistic pathogen, 
implying that it is routinely present in what is considered to be a healthy mucosal microflora 
while retaining the ability to establish an infection in its host if the factors are favourable. 
2.2.4 Clinical Classification Of Candidiasis: 
Infectious diseases: 
 Mucocutaneous manifestations 
o Oral : thrush, stomatitis, glossitis, chelitits 
o Alimentary : esophagitis, gastritis 
o Vulvovaginitis, balanitis, balanoposthitis 
o Chronic mucocutaneous candidiasis 
o Ocular candidiasis 
 Cutaneous manifestations 
o Paronychia ,Onychomycosis, Diaper dermatitis ,Candidal granuloma 
 Systemic manifestations 
o Urinary tract infection, Endocarditis, Pulmonary candidiasis, Meningitis, Arthritis 
Osteomyelitis, Endophthalmitis, Candidemia, Disseminated candidiasis 
Allergic diseases: 
 Candidids, Eczema, Asthma, Gastritis  
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2.3 Genitourinary Candidiasis: 
2.3.1 Definition of Genitourinary Candidiasis : 
Vulvovaginal Candidiasis: 
The presence of Candida in the vagina, in the absence of immunosuppression or damaged 
mucosa is usually not associated with any signs of disease and is thus referred to as colonization. 
In contrast to asymptomatic colonization, VVC is defined as signs and symptoms of 
inflammation in the presence of Candida species and in the absence of other infectious etiology. 
Over a decade ago, VVC was classified into uncomplicated and complicated cases, a 
classification that has been internationally accepted and adapted (Pappas et al and Sobel et al).  
Uncomplicated VVC is characterized by sporadic or infrequent occurrence of mild to moderate 
disease caused by C. albicans in immunocompetent women. 
 Complicated VVC includes cases of 
 Severe VVC 
 VVC caused by non-C. albicans species 
  VVC associated with pregnancy or other concurrent conditions such as uncontrolled 
diabetes or immunosuppression 
 Recurrent VVC (RVVC) in immunocompetent women. 
 RVVC is defined as at least four episodes of VVC during 1 year. RVVC can be further broken 
down into two subgroups: primary and secondary RVVC. Primary infections are idiopathic and 
do not correlate to any known predisposing factors identified with acute VVC (Sobel et al, 
1998). Secondary infections are defined as frequent episodes of acute VVC brought on by 
unavoidable predisposing factors such as diabetes mellitus or hormone replacement therapy.  
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Long-term suppressive antifungal therapy is commonly required to control RVVC and 
recurrence rates of up to 40% to 50% occur after discontinuation of suppressive therapy (Sobel et 
al, 2004). Compared to the case for women with other chronic vaginal symptoms, symptoms of 
women with RVVC are reported to have the greatest negative impact on work and social life  
Candiduria: 
This presentation is relatively rare, manifesting as cystitis (more commonly caused by Candida 
glabrata) and pyelonephritis, either ascending from a bladder infection or from hematogenous 
spread from a distant primary site of infection. The CFU criteria to diagnose candiduria range 
from 103 to 105 CFU/ml of urine. Chabasse et al study showed an significant correlation between 
heavy candiduria (>104 CFU/ml urine) and a high Pittet Candida colonization index (>0.5) has 
been established 
2.3.2 Epidemiology of Genitourinary Candidiasis: 
 VVC: 
Studies of Bauters et al and Beigi et al showed that Candida species mostly C. albicans, can be 
isolated in the vaginal tracts of 20 to 30% of healthy asymptomatic non pregnant women at any 
single point in time and in up to 70% if followed longitudinally over a 1-year period. If the 
balance between colonization and the host is temporarily disturbed, Candida can cause disease 
such as VVC which is associated with clinical signs of inflammation. Such episodes can happen 
sporadically or often can be attributed to the presence of a known risk factor like the disturbance 
of local microbiologic flora by antibiotic use. 
VVC is not a reportable disease and is often diagnosed without confirmatory tests and treated 
with over-the-counter medications, and thus the exact incidence is unknown. It is estimated that 
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around 75% of all women experience at least one episode of VVC during their childbearing 
years, of which about half have at least one recurrence (Sobel et al, 1998). 
Candiduria: 
Incidence numbers given for candiduria are dependent on the setting and the populations studied 
and have to be carefully compared because of the discrepancies with definitions of candiduria. 
Schaberg et al and Kauffman et al studies shows that candiduria is very common in hospitalized 
patients . There is evidence that the incidence is linked to antibiotic usage (Weinberger et al). In 
general, most estimates of incidence based on culture results are likely underestimated because 
standard urine culture is not very sensitive. 
 Depending on the population examined, Candida is reported in up to 44% of urine samples sent 
for cultur . Colodner et al and De Francesco et al report lower rates (0.14 to 0.77% and 0 to 
1.4%) in urine cultures from both hospitalized patients and outpatients. The incidence of 
candiduria also varies with hospital setting, being most common in intensive care units (ICUs) 
(Schaberg et al) and among those in burn units (Bougnoux et al).  Studies by Richard et al and 
Lundstorm et al reported that 11 to 30% of nosocomial urinary tract infections (UTIs) are caused 
by Candida.  
2.3.3 Predisposing Risk Factors For Genitourinary Candidiasis: 
Risk Factors for VVC: 
Although many healthy women develop VVC sporadically, several behavioral and host-related 
risk factors have been associated with VVC and recurrent episodes. These episodes are caused 
by Candida overgrowth from the gastrointestinal or the vaginal tract or through sexual 
transmission (Reed et al). Studies by Cetin et al and Foxman et al showed that Behavioral risk 
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factors like frequent sexual intercourse and receptive oral sex, as well as the use of high-estrogen 
oral contraceptives, condoms, and spermicides have been significantly associated with a higher 
incidence of VVC. Host-related risk factors that have been significantly associated with VVC 
and RVVC include antibiotic use, uncontrolled diabetes, conditions with high reproductive 
hormone levels  and genetic predispositions (Goswami et al).  
After antibiotic use, the increase in vaginal colonization with Candida species  mostly Candida 
albicans is estimated to range from 10 to 30% and VVC occurs in 28 to 33% of cases by Sobel in 
2007as antibiotics alter the bacterial microflora of the vaginal and gastrointestinal tracts and thus 
allow for overgrowth of Candida species.  It is commonly hypothesized that the reduction of 
lactobacilli in the vaginal tract predisposes women to VVC. Lactobacilli play a key role in the 
vaginal flora through the production of hydrogen peroxide, bacteriocins, and lactic acid which 
protect against invasion or overgrowth of pathogenic species (Eschenbach et al). However, 
studies by Vitali et al and Zhou et al have failed to provide evidence that an altered or abnormal 
vaginal bacterial flora predisposes women to recurrent episodes of VVC in the absence of 
antibiotic intake.  
Episodes of VVC occur mostly during childbearing years and are rare in premenarchal and 
postmenopausal women. An increased frequency of VVC has been reported during the 
premenstrual week (Eckert et al) and during pregnancy (Cotch et al).  
VVC and Diabetes: 
A study by Faraji et al showed that the prevalence of candiduria among diabetic women was 
20%. The species of Candida isolated in this study were C. albicans (62.5%), C. glabrata 
(18.7%), Candida tropicalis (9.4% ) and Candida parapsilosis (9.4%) with C. albicans as the 
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most predominant  isolate. Another study by Emeribe et al showed that the prevalence was about 
14%. 
Risk Factors for Candiduria: 
Studies by Kauffman et al and Lundstorm et al have identified similar risk factors associated 
with candiduria in adults. They include anatomic urinary tract abnormalities, comorbidities, 
indwelling urinary drainage devices, abdominal surgery, ICU admission, broad-spectrum 
antibiotics, diabetes mellitus, increased age, and female sex. The patients who present with 
candiduria from the community are younger, more commonly female, pregnant and more likely 
to have dysuria.  
Candiduria and diabetes:  
A study by Janifer et al in South India showed that 13% of UTI in diabetic patients was caused 
by Candida. Among the specimens containing Candida,57 (80.3%) were other Candida 
species and 14 (19.7%) were Candida albicans. Poor glycemic control was significantly 
associated with UTI in both sexes. Age, duration of diabetes, and glycemic control did not show 
any significant differences between men and women. 
Yismav G et al showed that significant candiduria was detected in 29 of 387 (7.5%) and 6 of 35 
(17.1%) asymptomatic and symptomatic diabetic patients, respectively. The overall prevalence 
of significant candiduria was 35 of 422 (8.3%). Of the 38 Candida species isolated, C. albicans 
accounted for 42% of the cases, followed by C. glabrata (34.2%),C tropicalis (15.8%), C.famata 
(5.3%) and C.kefyr (2.6%). 
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2.3.4 Virulence Factors Of Candida Pertaining To Genitourinary Candidiasis: 
 Bud-Hypha Formation 
 Aspartic Proteinases and Phospholipases  
 Adhesion Proteins  
 Biofilm Formation 
 Phenotypic Switching 
2.4 Laboratory Diagnosis of Genitourinary Candidiasis: 
2.4.1 Direct Examination: 
The preferred method for the direct microscopic examination of genitourinary candidiasis 
incudes  
(i) Wet mount  
(ii) KOH mount  
Processing of the specimen does not generally require treatment with keratinolytic substance. 
Wet mounts can be unstained, prepared in saline or stained with lactophenol cotton blue or 
calcofluor white. About 50% of patients have positive microscopy of a wet mount or saline 
preparation, where yeast cells and hyphal elements can be seen. A 10% potassium hydroxide 
(KOH) preparation is more sensitive than a saline preparation in identifying yeast cells or hyphae  
Microscopic examination of specimens from candidiasis will demonstrate the presence of 
budding yeast cells, pseudohyphae and/ or hyphae. Demonstration of hyphal elements in direct 
microscopic examination is important as Candida species normally colonises the oral mucosa 
and the presence of the hyphal elements in addition to the yeasts, is an indicator of infection. 
However C.glabrata, a significant non-albicans Candida species does not produce hyphae or 
pseudo hyphae in clinical specimens 
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2.4.2 Culture: 
Vaginal culture is the most accurate method for the diagnosis of VVC and is indicated if 
microscopy is negative but VVC is suspected or in cases of high risk for non-C. albicans VVC.  
Candida species grow on almost all common laboratory media particularly Blood agar and 
Sabouraud’s dextrose agar with antibacterial antibiotics for primary isolation. 
Isolation of Candida: 
Sabourauds Dextrose Agar with antibiotics: 
The routine medium used for isolation of fungi in culture from mucocutaneous infections is 
Sabouraud’s dextrose agar supplemented with antibiotics like Gentamicin , Chloramphenicol or 
Tetracycline to prevent bacterial overgrowth. The addition of cycloheximide to inhibit fungal 
contaminants permits the growth of Candida albicans but inhibits most strains of C.tropicalis, 
C.krusei and C.parapsilosis. Use of two SDA containing chloramphenicol supplemented with or 
without cycloheximide is recommended. 
Cultures can be incubated at 28⁰ C or / and at 37⁰ C.Candida colonies appears in two to three 
days and more than three days for some Candida species like C. guillermondii and C.glabrata. 
In case of isolation of candida from urine, >10⁵ colony forming units/ml can be considered 
significant. 
Colony Characteristics and Microscopic Morphology of Candida on SDA: 
 Candida albicans 
(i) Macroscopically – Colonies are smooth , creamy , pasty , glistening 
(ii) Microscopically – globose or short ovoid cells(5 - 7 μm) 
 Candida tropicalis 
(i) Macroscopically – white to cream coloured colonies with peripheral fringe 
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(ii) Microscopically – globose – ovoid or short ovoid cells (4 -8 μm X 5-11 μm) 
 ·Candida krusei 
(i) Macroscopically - Colonies are flat ,dry becoming dull, smooth or wrinkled with the 
dense of mycelium extending as lateral fringe around the colony 
(ii) Microscopically - Cylindrical , few ovoid cells / elongated cells (3-5 μm x 6-20μm) 
 Candida parapsilosis 
(i) Macroscopically – Soft, smooth, white sometimes lacy 
(ii) Microscopically – Short ovoid to long ovoid cells ( 2.5 - 4μm x 2.5 -9 μm) 
 ·Candida guilliermondii 
(i) Macroscopically – Thin , flat, glossy , cream to pinkish colonies 
(ii) Microscopically - short ovoid / ovoid cells( 2-5 μm x 3-7 μm) 
 Candida glabrata 
(i) Macroscopically-Cream coloured, soft, glossy ,smooth colony 
(ii) Microscopically-small, round yeasts (2.5 – 4.5 μm x 4-6 μm) 
 Candida kefyr 
(i) Macroscopically- Smooth , creamy appearance 
(ii) Microscopically- short, ovoid with a few elongate cells(2.5 -5 μm x 5-10 μm) 
2.4.3 Speciation of Candida: 
Germ Tube Test (Reynolds Braude Phenomenon): 
A germ tube is defined as a filamentous extension from a yeast cell that is about half the width 
and three to four times the length of the cell. The principle of the test is the ability of Candida 
albicans or Candida dubliniensis to produce germ tube when incubated in serum at 37⁰ C for 
two hours. 
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 It helps in the presumptive identification of Candida albicans or Candida dubliniensis. A true 
germ tube has no constriction at the point of origin. Early pseudohyphae of Candida tropicalis 
may be confused but characteristically show a point of constriction adjacent to the mother cell. 
C.albicans and its variants are able to produce germ tube when incubated with various 
substances like human or sheep serum, rabbit plasma, egg albumin, thioglycollate broth and 
various peptone medium at 370C for 2 hours. 
CHROM agar: 
A new differential culture that allows selective isolation of yeasts and presumptive identification 
of most commonly isolated Candida species especially Candida albicans, Candida tropicalis 
and Candida krusei. Identification of yeast pathogen by traditional methods requires several days 
and specific mycological media. Chromogenic media contain chromogenic substrates which 
react with enzymes secreted by the target microorganisms to yield colonies of varying colours 
after incubation at 370 C for 48 to 72 hours. 
Cornmeal Agar: 
The commonly used differential medium both for genus identification as well as speciation is the 
Corn meal Agar plate (Dalmau plate) supplemented with Tween 80 (Polysorbate 80) or Rice 
starch agar 
Corn meal agar is a general purpose medium used for the isolation of fungi. In 1960, Walker and 
Huppert modified the basic formulation by adding polysorbate 80 which stimulated rapid and 
abundant chlamydospore formation. Dextrose is added to Corn meal agar to enhance fungal 
growth and pigment production. 
Subcultures made by furrowing the Corn meal agar plates with coverslips applied on the streak 
line and incubated at 280C for 2-5 days. Cover slips applied provides a microaerophilic 
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environment which enhances the formation of hyphae and blastoconidia and the polysorbate 80 
reduces the surface tension. After 2-5 days of incubation, plates are examined directly under the 
microscope for the presence of pseudo hyphae/ true hyphae, chlamydospores , arthroconidia and 
blastoconidia. 
Chlamydospore formation are seen in the isolates of C.albicans and C.dubliniensis. 
C.dubliniensis often produces chlamydospores abundantly in clusters. 
Microscopic Morphology of different species on Corn Meal Agar: 
 C.albicans –Hyphae and pseudohyphae formed with clusters of blastospores at internodes 
and large thick walled terminal chlamydospores 
 C.tropicalis- Abundant long, branching pseudohyphae .Ovoid / elongate pseudohyphae 
found anywhere along the pseudohyphae .True hyphae may be present. 
 C.krusei – Pseudohyphae with elongated blastoconidia in tree like arrangements / 
Crossed match stick appearance 
 C.parapsilosis- Fine pseudomycelium with single or small clusters of blastoconidia. 
Thick pseudo mycelium and giant cells also found. 
 C.glabrata –No pseudohyphae. Small, spherical and tightly compacted blastoconidia 
 C.guilliermondi –Pseudohyphae with blastospores in small chains or in clusters 
 C.kefyr –Abundant pseudomycelium of elongate cells that lie parallel giving log in 
stream appearance. Blastoconidia are infrequent. 
2.4.4 Biochemical Characterisation: 
Biochemical speciation of Candida is based on 
1) Assimilation tests 
2) Fermentation tests. 
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Candida species can utilize carbohydrates both oxidatively (assimilation) & anaerobically 
(fermentation) .Yeasts possessing the ability to ferment a given carbohydrate do also assimilate 
that substance but not necessarily vice versa. 
Sugar assimilation tests: 
Sugar assimilation determines the ability of particular yeast to utilize a particular carbohydrate as 
the sole source of carbon in the presence of oxygen. Carbohydrate utilization patterns are the 
most commonly used conventional methods for the definitive identification of yeast recovered in 
a clinical laboratory. 
 Auxanographic methods 
 Commercial Kits 
Sugar fermentation test: 
The classic tests involved liquid media supplemented with different carbohydrates, a colour 
indicator to assess pH changes to measure acid formation and the Durham’s tube to assess gas 
production .There are several modifications for assessment of gas production such as use of 
semisolid media or a wax layer on top of liquid medium. Production of gas and not the change of 
colour in the fermentation fluid is considered as the indicator of positive fermentation 
2.4.5 Growth in Sabourauds Dextrose broth: 
This method serves as an important differentiating method for various Candida species. Ring 
around the surface of the tube at the broth interface indicates Candida tropicalis, a thick pellicle 
creeping along the sides indicates C.krusei while growth occurring at the bottom indicates other 
Candida species. 
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2.4.6 Automated methods: 
The species of Candida can be identified within a day by using automated/semiautomated 
systems such as Vitek 2 or ID32C yeast identification systems which are based on phenotypic 
identification 
2.4.7 MALDI- TOF: 
Matrix-Assisted Laser Desorption/Ionization-Time Of Flight Mass Spectrometry (MALDI-TOF 
MS), based on protein fingerprints, has been used for the identification of clinical Candida spp. 
isolates. Even closely related species/species complexes have been identified by MALDI-TOF 
MS within a few minutes. 
2.4.8 Molecular Methods: 
i) Use of specific DNA probes like those encoding for actin gene, part of the 18s RNA gene 
complex, chitin synthetase gene, mitochondrial DNA or Candida DNA Repititive Elements 
ii) Electrophoretic patterns of DNA 
iii) RNA profiling 
iv Restriction enzyme analysis 
v Amplification techniques like Polymerase chain reaction 
2.5 Treatment of Genitourinary Candidiasis: 
2.5.1 Treatment of VVC: 
Treatment recommendations for VVC are separated into treatment of uncomplicated VVC 
caused by C. albicans and of complicated VVC, which includes RVVC, severe VVC, VVC 
caused by non-C. albicans species, and VVC in immunocompromised hosts (Workowski et al). 
In cases of complicated VVC, contributing factors such as diabetes or behavioral factors should 
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be controlled or avoided. Treatment should not differ on the basis of HIV infection (Pappas et 
al). 
2.5.2 Treatment of uncomplicated VVC: 
Successful treatment of uncomplicated VVC is achieved with single-dose or short-course therapy 
in over 90% of cases. Several topical and oral drugs are available, without evidence for 
superiority of any agent or route of administration, although among the topically applied drugs, 
azoles are more effective than Nystatin. As an oral agent, Fluconazole at 150 mg as a one-time 
dose is recommended for uncomplicated VVC. Because oral and topical antimycotics have 
shown to achieve equivalent results for the treatment of VVC (Watson et al), both Fluconazole 
given orally and topical agents have received the same recommendation in the IDSA guidelines 
(A-1) and no preference is given to either treatment (Pappas et al).  
2.5.3 Treatment of complicated VVC and RVVC: 
Complicated VVC with azole-susceptible strains requires topical therapy administered 
intravaginally daily for at least 7 days or multiple doses of oral Fluconazole (150 mg every 72 h 
for three doses) (Sobel, 2001). In cases of RVVC, 10–14 days of induction therapy with a topical 
agent or oral Fluconazole, followed by Fluconazole, 150 mg weekly for 6 months is 
recommended. Long-term suppressive therapy with oral Fluconazole is the most convenient and 
well-tolerated regimen among other options and was shown to be effective in over 90% of 
patients with RVVC. Against expectations, study by Sobel in 2004 have shown little evidence of 
developing Fluconazole resistance in C. albicans isolates or superinfection with non -
C.albicans species in patients on suppressive therapy with Fluconazole . However, species 
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identification and MIC testing should be performed in women experiencing breakthrough or 
refractory infection. Other oral treatment options that have been shown to be effective for RVVC 
with azole-susceptible strains include suppressive therapy with Ketoconazole (100 mg daily) 
(Sobel, 1985) and with Itraconazole (200 mg twice daily for one day each month) (Witt et al). 
However because of liver toxicity associated with oral Ketoconazole , other regimens are now 
preferred as maintenance therapy.  
Non-Candida albicans-related disease is less likely to respond to azole therapy (Nyirjesy et al). 
For C.glabrata vulvovaginitis that is unresponsive to oral azoles, topical intravaginal boric acid, 
administered in a gelatin capsule, 600 mg daily, for 14 days is an alternative.Another alternative 
agent for C. glabrata infection is Nystatin intravaginal suppositories, 100 000 units daily for 14 
days .A third option for C. glabrata infection is topical 17% Flucytosine cream alone or in 
combination with 3% AmB cream administered daily for 14 days (Pappas et al). 
2.5.4 Treatment of Candiduria: 
The presence of yeast in the urine, whether microscopically visualized or grown in culture, must 
be evaluated in the context of the clinical setting to determine its relevance and make an 
appropriate decision about the need for antifungal therapy. Similar to the case for asymptomatic 
bacteriuria, there has been a revolving debate on whether and how to treat patients with 
candiduria (Nicolle et al).  
2.5.5 Treatment of asymptomatic Candiduria: 
The current guidelines recommend observation of asymptomatic patients and elimination of 
predisposing factors if feasible. Specifically, removal of an indwelling catheter may be sufficient 
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to eliminate candiduria without antifungal therapy.  Treatment with antifungal agents is not 
recommended unless the patient belongs to a group at high risk for dissemination; high-risk 
patients include neutropenic patients, very low-birth-weight infants and patients who will 
undergo urologic manipulation. Neutropenic patients and very low–birth-weight infants should 
be treated as recommended for candidemia with prolonged high-dose antifungal intravenous 
therapy. Patients undergoing urologic procedures should be treated with oral Fluconazole 400 
mg (6 mg/kg) daily or AmB deoxycholate 0.3–0.6 mg/kg daily, for several days before and after 
the procedure 
2.5.6 Treatment of symptomatic Candiduria: 
For Fluconazole-susceptible organisms, oral Fluconazole 200 mg (3 mg/kg) daily for 2 weeks is 
recommended. For Fluconazole-resistant C. glabrata, AmB deoxycholate 0.3–0.6 mg/kg daily 
for 1–7 days or oral Flucytosine 25 mg/ kg 4 times daily for 7–10 days is recommended. For     
C.krusei, AmB deoxycholate 0.3–0.6 mg/kg daily, for 1–7 days is recommended. Removal of an 
indwelling bladder catheter if feasible is strongly recommended. AmB deoxycholate bladder 
irrigation 50 mg/L sterile water daily for 5 days may be useful for treatment of cystitis due to 
Fluconazole-resistant C. glabrata and C. krusei species. 
2.6 Anti Fungal Drug Resistance: 
Microbiological resistance refers to non-susceptibility of a fungus to an antifungal agent by in 
vitro susceptibility testing, in which the MIC of the drug exceeds the susceptibility breakpoint 
for that organism. Microbiological resistance can be primary (intrinsic) or secondary (acquired).  
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Primary resistance is found naturally among certain fungi without prior exposure to the drug 
and emphasizes the importance of identification of fungal species from clinical specimens. 
Resistance of Candida krusei to Fluconazole is an example.  
Secondary resistance develops among previously susceptible strains after exposure to the 
antifungal agent and is usually dependent on altered gene expression. The development of 
Fluconazole resistance among Candida albicans strains illustrates this type of resistance.  
Clinical resistance is defined as the failure to eradicate a fungal infection despite the 
administration of an antifungal agent with in vitro activity against the organism. Such failures 
can be attributed to a combination of factors related to the host, the antifungal agent or the 
pathogen. Although clinical resistance cannot always be predicted, it highlights the importance 
of individualizing treatment strategies on the basis of the clinical situation. 
2.6.1 Mechanism of Action of Azoles:  
Azoles exert their action by inhibiting the lanosterol 14-α-demethylase (Erg11p), which is 
involved in the biosynthesis of ergosterol. Erg11p is a cytochrome P450 enzyme from family 51 
(CYP51) encoded by the ERG11 gene. This enzyme converts lanosterol to ergosterol, which 
catalyses the oxidative removal of the 14α-methyl group from lanosterol. The sterol 14-α-
demethylase contains a heme moiety in its active site. The unhindered nitrogen of the azoles 
binds to the heme iron of Erg11p, thus inhibiting enzymatic reaction. In addition, second 
nitrogen in the azoles has the potential to interact directly with the apoprotein of lanosterol-
demethylase.  
 2.6.2 Epidemiology of Azole Resistance: 
 Widespread use of Itraconazole and Fluconazole is thought to have been the major driver of 
azole resistance. Up to one-third of patients with advanced AIDS in one study harbored 
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Fluconazole-resistant C. albicans in their oral cavities (Law et al). Azole-resistant C. albicans is 
less common among patients with other diseases, such as vaginal candidiasis and candidemia 
(Sanglard et al). In general, the rates of azole resistance among the most commonly encountered 
invasive Candida species remain low, with reported rates of 1.0%–2.1% in Candida albicans, 
0.4%–4.2% in Candida parapsilosis, and 1.4%–6.6% in Candida tropicalis [Pfaller et al,2005]. 
A clear exception is C.glabrata, which is second to C.albicans in causing systemic fungal 
infection. According to data from the ARTEMIS Global Antifungal Surveillance Program, the 
incidence of Fluconazole resistance in C.glabrata increased from 7% in 2001 to 12% in 2004. In 
addition to the changing trends in antifungal susceptibility, there has been a recent shift towards 
more infections in the immunocompromised host being caused by Candida species other than 
Candida albicans as shown in the study by Hajjeh et al. Studies by Abi-Said et al and Price et al 
have initially incriminated the environmental pressure imposed by exposure to Fluconazole. 
Other factors such as exposure to antibacterial agents, immunosuppressive therapy, and the 
underlying medical condition of the host might also prove to be better predictors of the 
distribution of Candida species than Fluconazole.  
2.6.3 Azole resistance in diabetics: 
The genus of Candida is commensal to the human gastrointestinal and genitourinary tract. In 
patients suffering with DM, an extra glucose level in the bloodstream can cause several 
infectious diseases ranging from superficial candidiasis to deep seated mycoses. As a major 
component of the culture medium, carbon source plays an important role in the growth of 
microorganisms including Candida species. Carbon compounds generally range from sugars to 
organic acids, alcohols, polysaccharides whereas microbes prefer simple sugars such as glucose, 
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sucrose, maltose and lactose for their rapid growth and these simple sugars increases the fungal 
population density. Fungal load or count is an important parameter of antifungal susceptibility. 
Mandal  et al investigated the antifungal drug susceptibility in culture medium containing 
different antifungal agents in combination with fixed concentrations of glucose in each set of 
experiments and demonstrated the failure of azole (Voriconazole) followed by polyene (AmpB) 
antifungal agent in the presence of high glucose in medium. Antifungal agents showed a 
decreased rate of susceptibility when the glucose concentration in culture medium was increased. 
Rodaki et al. conducted a study based upon the global impact of glucose on 
C.albicans transcriptome for the modulation of carbon assimilatory pathways during 
pathogenesis.The study revealed that glucose concentrations in the bloodstream have a 
significant impact upon C. albicans gene regulation which reflects on the elevated resistance to 
oxidative, cationic stresses and resistance to an azole antifungal agent, Miconazole. In this study, 
it was observed that no significant susceptibility level was observed for Anidulafungin whereas 
Voriconazole becomes the most resistant followed by Amphotericin B.  
The in vitro antifungal susceptibility testing by Al-Attas et al revealed that the yeast isolated 
from the diabetic patients had different rates of resistance to the tested antifungal drugs except 
amophotericin B and nystatin, against which they had no resistance . In contrast, in the healthy 
controls, none of the isolated yeast showed any resistance to the tested antifungal agents. When 
patients with different types of DM were compared, there was statistically no significant 
difference in the antifungal susceptibility.  
2.6.4 Mechanisms of Azole Resistance: 
Many mechanisms of resistance to azoles have been described in Candida species. More than 
one mechanism can be functioning in any given fungal strain with additive effects. 
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Reduced intracellular accumulation of azoles: 
 Interactions between sterols and phospholipids in the cytoplasmic membrane affect membrane 
fluidity and asymmetry and consequently influence the transport of materials across the 
membranes.  
A decrease in the amount of azoles taken up by the fungal cell may result from changes in the 
sterol and/or the phospholipid composition of the fungal cell membrane. Intracellular 
accumulation of azoles can hence be reduced by the lack of drug penetration because of low 
ergosterol levels or possibly decreased ratio between phosphatidyl-choline and phosphatidyl-
ethanolamine in the plasma membrane, which may change the membrane barrier function 
[Loeffler e al].  
However, an important cause of reduced intracellular accumulation of the drug is active efflux of 
the drug out of the cell. In C.albicans, two families of drug efflux pumps are described: ATP-
binding cassette (ABC) transporters and major facilitator (MF) proteins. These efflux pumps 
differ in their energy source for transport: ABC transporters use adenosine triphosphate (ATP) as 
energy source for transport; MFs use the proton gradient across the membrane as the driving 
force for transport. In C.albicans, ABC transporters are encoded by CDR (Candida drug 
resistance) genes, whereas the MF transporters are encoded by the MDR1 (multidrug resistance) 
gene. Several clinical azole-resistant isolates of Candida species are unable to accumulate 
sufficient concentrations of intracellular azoles to inhibit growth due to overexpression of genes 
encoding drug efflux pumps. Direct evidence for the involvement of efflux pumps in azole 
resistance was presented by Niimi . In this study, overexpression of CDR1 in a C. albicans cdr1 
deletion mutant conferred resistance to Fluconazole. These molecular mechanisms were 
evaluated by Sanguinetti et al in 29 clinical C.glabrata isolates of which 20 isolates were 
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Fluconazole resistant and 9 were susceptible dose dependent to Fluconazole . It became apparent 
that the upregulation of the CgCDR1-, CgCDR2- and CgSNQ2- encoded ABC transporter 
proteins might explain the azole resistance in these isolates. 
 Alteration of membrane sterol: 
Some of the earliest studies on azole resistance pointed to alterations in sterol biosynthesis other 
than those caused by the ERG11 gene product. Growth inhibition by azoles in Candida is caused 
by ergosterol depletion and its replacement by the toxic 14α-methyl-3, 6-diol. This growth arrest 
can be circumvented if 14α methylfecosterol accumulates instead. This change in sterol 
accumulation and azole resistance is achieved if cells are deficient in sterol Δ5,6-desaturase, 
encoded by the ERG3 gene . The altered sterol composition of ERG3 deletion mutants allows 
growth during azole treatment and the production of functional membranes Recent research by 
Kelly et al using 7 Itraconazole-resistant C.dubliniensis isolates demonstrated that mutation of 
their ERG3 gene and the consequent loss-of-function of Erg3p was an important mechanism of 
in vitro Itraconazole resistance in six out of the seven C dubliniensis derivatives.  
Altered cell wall composition: 
In Fluconazole-resistant C.albicans strains, a change in GAP profile in the cell wall was 
observed by Angiolella et al as compared to the GAP profile of susceptible C.albicans strains. In 
Fluconazole-resistant strains, the GAP proteins enolase and phosphoglyceromutase disappeared, 
whereas larger amounts of β-1,3-glucanase and of polydisperse, high-molecular, highly-
glycosylated material appeared. Hence, this overall change from a prevalently “glycotic” one 
(rich in the GAP proteins enolase and phosphoglyceromutase) to a prevalently “glucanase” one 
may be seen as a general reaction to an inhibitor, a reaction that may be stably incorporated into 
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a resistant strain as a sort of anti-stress response because it offers the cell some selective 
advantages .  
Since the glycolytic enzymes are highly antigenic, thus their decreased levels of expression in 
the cell wall may render the cell less antigenic, therefore helping the cell to evade the host’s 
immune responses.(Chaffin et al)  
Overproduction of the target enzyme of azoles: 
 Upregulation of the ERG11 gene, encoding the major target enzyme of the azoles lanosterol 
14α-demethylase, has been observed in azole-resistant C.albicans and C.glabrata isolates by 
Chau et al. However, studies by Sanguinetti et al reported no significant change in expression 
levels of the ERG11 gene in azole-resistant clinical isolates of C. glabrata.  
Alterations in the target enzyme of the azoles: 
 A successful approach to demonstrate the involvement of ERG11 mutations in Fluconazole 
resistance has been the heterologous overexpression of different ERG11 alleles and comparison 
of the susceptibility of the resulting strains to Fluconazole [Sangard e al]. The amino acid 
changes G129A, Y132H, S405F, G464S and R467K were shown to cause Fluconazole 
resistance. Direct evidence for certain mutations resulting in decreased affinity to the drug were 
provided by biochemical analysis of heterologously expressed enzymes. The affinity of 
Fluconazole for lanosterol 14α-demethylase containing the mutations Y132H, G464S or R467K 
was reduced as compared with the wild-type enzyme, confirming that these naturally occurring 
mutations indeed caused drug resistance in clinical C.albicans isolates [Lamb et al].   
Multiple mechanisms contribute to a stepwise development of azole resistance : 
Each of the mechanisms described above can cause resistance of Candida species to azoles. 
Several studies have shown that multiple mechanisms may be combined to result in a stepwise 
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development of azole resistance. Widespread and prolonged use of azoles has led to the rapid 
development of the phenomenon of multiple drug resistance (MDR), which poses a major hurdle 
in antifungal therapy. 
 
2.7 Antifungal Susceptibility Testing: 
The rising prevalence of serious fungal infections and antifungal drug resistance has created an 
increased demand for reliable methods of in vitro testing of antifungal agents that can assist in 
their clinical use. 
Invitro susceptibility tests are mainly used for 
1. Epidemiological surveys for determination of susceptibility profiles and resistance rates of the 
infecting strains against commonly used antifungal drugs at a particular center. 
2. Determination of the degree of antifungal activity of the newly developed compounds 
3. Prediction of clinical outcome and optimization of antifungal therapy in routine mycology 
laboratory practice. 
 
Methods used for in vitro antifungal susceptibility testing of Yeasts are 
2.7.1 Disk Diffusion method: 
Agar disk diffusion is a simple, flexible and cost effective alternative to broth dilution testing. 
CLSI subcommittee has proposed a standard disk diffusion method for susceptibility testing of 
Candida species to the Fluconazole and Voriconazole. The subcommittee has established zone 
interpretative criteria for Fluconazole and Voriconazole .CLSI recommends MHA medium 
supplemented with 2% glucose and 0.5μg/ml of methylene blue over RPMI agar because of less 
intrazonal growth. It also recommends the inoculum size of 0.5 McFarland standard and 
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incubation temperature of 35⁰ C for 20 to 24 hr but some strains may require 48 hr incubation. 
Addition of a low concentration of methylene blue (0.5μg/ml) makes the zones of inhibition 
clearer and easier to measure precisely. 
2.7.2 Broth microdilution method.  
The Clinical and Laboratory Standards Institute developed and published an approved reference 
method for the broth microdilution testing (CLSI document M27-A3) of Candida species. The 
standard powders of Fluconazole , Amphotericin B , Voriconazole  And Caspofungin  are used 
as antifungals with Distilled water  as a solvent for Fluconazole and Caspofungin and DMSO 
(dimethylsulphoxide) as a solvent for water-insoluble Amphotericin B and Voriconazole. The 
stock solutions can be  prepared at the rate of 1280 μg/mL for Fluconazole, 1600 μg/mL for 
Amphotericin B, 1600 μg/mL for Voriconazole, and 1600 μg/mL for Caspofungin. For the 
susceptibility test, RPMI 1640 (with glutamine, bicarbonate-free, and containing phenol red as 
the pH indicator) is used as a medium. The final concentrations should be in the range 64–
0.125 μg/mL for Fluconazole, 16–0.03 μg/mL for Amphotericin B and Voriconazole, and 8–
0.015 μg/mL for Caspofungin.. The results should be evaluated 24 hours later for Caspofungin 
and 48 hours later for Fluconazole, Amphotericin B, and Voriconazole. For Amphotericin B, the 
MIC endpoint is defined as the lowest drug concentration that resulted in a reduction in growth 
by 90% or more compared with that of a drug-free growth control well. For Fluconazole, the 
MIC endpoint is defined as a 50% reduction in optical density. For Caspofungin, the endpoint is 
given as the concentration of the drug in the assay at which 50% of growth control was 
observed.  
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2.7.3 Epsilometer test (E- test) 
E-test uses a non-porous plastic strip immobilised with a predefined gradient of a given 
antimicrobial agent on one side and printed with an MIC on the other side. The medium that 
provides the best performance for E-test MICs is solidified RPMI supplemented with 2% 
dextrose. When the strip is placed on an inoculated agar plate, a continuous, stable and 
exponential antimicrobial gradient is established along the side of the strip. After incubation, the 
MIC value can be read directly from the MIC scale printed on the strip 
2.7.4 Colorimetric and spectrophotometric methods: 
A novel alternative to the standard method of visual grading of turbidity is the use of 
colorimetric methods for the determination of MIC endpoints. The colorimetric method using 
2,3-Diphenyl-5-thienyl-(2)-tetrazolium chloride (STC) which is an oxidation-reduction 
indicator that, in the presence of growing organisms, changes from colorless to red is 
identical to the broth microdilution method with two exceptions: STC was added to RPMI 
1640-morpholinepropanesulfonic acid medium with antifungal agents at a concentration of 
100 μg/ml (final STC concentration, 50 μg/ml) and the solubilizing agents were added at 
48hr of incubation and plates were incubated for 2 hrs. The MICs were determined by three 
methods: visual reading before the addition of solubilizing agents, visual reading after the 
addition of solubilizing agents  and spectrophotometer determination after solubilization at 
540 nm. 
 2.7.5 Flow cytometric methods: 
Flow cytometric methods have been used for antifungal susceptibility testing by introducing 
DNA- binding vital dyes into the culture to detect fungal cell damage after exposure to an 
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antifungal agent. Inspite of faster results, the need for flow cytometer preclude their use in small 
laboratories  
2.7.6 Automated system: 
Vitek 2 system provides a very promising alternative to reference methods for antifungal 
susceptibility testing of isolates belonging to the most clinically relevant Candida species, thus 
providing fast and reliable means for detecting azole resistance. Susceptibility testing with the 
Vitek 2 system can be performed by preparing a standardized 2.0 McFarland inoculum 
suspension and then  placing it in a Vitek 2 cassette along with a sterile polystyrene test tube and 
a Vitek 2 card containing serial twofold dilutions of Fluconazole (range, 1 to 64 μg/ml) and 
Voriconazole (range, 0.125 to 8 μg/ml). After the loaded cassettes are placed in the Vitek 2 
instrument, the cards are filled with the appropriately diluted yeast suspensions, incubated (for a 
maximum of 24 h)  and read automatically. The MIC results are expressed in μg/ml. 
2.7.7 Candifast 
The Candifast kit allows the identification of Candida species and testing of their susceptibility 
to various antifungal agents. It is a 20 well tray with two rows, one for identification and the 
other for susceptibility testing. The determination of the resistance of yeasts to antifungal agents 
is based on growth or absence of growth of the yeasts in the presence of various antifungal 
agents. An isolated colony of Candida should be inoculated into reagent-1 (R1) bottle and mixed 
well. The turbidity of the suspension should be then compared with the turbidity control. 100 µl 
of inoculated R1 was added to R2. 100 µl of R2 was then added to each of the wells, 2 drops of 
paraffin oil was added to each well and the test tray was sealed and incubated at 37°C for 24 
hours. Reading was taken once the yeast grew in the control well. The indicator used is phenol 
red. A yellow or orange-yellow color in the susceptibility test row, due to glucose fermentation, 
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indicated that the yeast was able to grow in the presence of the antifungal agent and hence was 
resistant to that drug. If the color in the well was red or pink, the isolate was inhibited by the 
drug in that well and so was sensitive to that drug. The susceptibility testing by Candifast kit can 
be done for the following anti-fungal drugs: Amphotericin B (4 µg/ml), Fluconazole (16 µg/ml), 
Ketoconazole (16 µg/ml), Nystatin (200 Units/Ml), Flucytosine (35 µg/ml), Econazole (16 
µg/ml) and Miconazole (16 µg/ml).  
2.7.8 Molecular methods for detection of ERG11 mediated resistance: 
Detection of ERG11 mutations by DNA sequencing: 
ERG11 genes obtained from the genomic DNAs of all C. albicans isolates are amplified by PCR 
with high-fidelity Pwo DNA polymerase. Fragments of the expected length (1.6 kb) obtained are 
sequenced in order to identify the point mutations present in the ERG11 genes of the resistant 
isolates. The sequences are compared with the published sequence of ERG11 for any variation. 
Globally, 11 amino acid substitutions were found to be associated with a resistance phenotype: 
D116E, G450E, G307S, Y132F, D446N, G464S, F126L, K143R, S405F, F449S, and T229A. On 
the other hand, two amino acid substitutions, K128T and V437I, were confirmed to not 
participate in azole resistance (Perea et al). 
Indirect detection of ERG11 expression by PCR: 
11 amino acid substitutions were found to be associated with a resistance phenotype: D116E, 
G450E, G307S, Y132F, D446N, G464S, F126L, K143R, S405F, F449S, and T229A. 
ERG11 expression can be evaluated by detecting point mutations which results in aminoacid 
substitutions using specific primers. Specific primers can be used to detect point mutation within 
the ERG11 gene that results in ERG11 overexpression as done by Kelly et al and Pam et al. 
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ERG 11 expreesion studies by Reverse transcriptase PCR: 
Total RNA was isolated using the RNeasy Mini Kit in accordance with the manufacturer's 
instructions. RNA quality and quantity were verified both electrophoretically and using a 
NanoDrop ND1000 Spectrophotometer. To avoid DNA contamination, the RNA samples were 
treated with RNAse-free DNase I .First-strand cDNA was synthesized from 0.5 µg total RNA 
using the Moloney-Murine Leukemia Virus (MMLV) reverse transcriptase and random hexamer 
oligonucleotides.  C. albicans ERG11 gene was amplified from the synthesized cDNA with 
primers. Moreover, actin (ACT) was established as a housekeeping gene to normalize the 
dissimilar RNA concentrations during RNA extraction. The RT reactions were performed in 
triplicate in a Thermocycler . The relative expression ratio was calculated by the conventional 
method based on concentration of PCR products as follows: fold change in target gene 
expression = target/reference ratio in experimental sample relative to target/reference ratio in 
untreated control sample. Gene with statistically significant (P≤0.05) variation and fold changes 
of ≥ 2-fold and ≤ 0.5 were classified as significantly up-regulated and down-regulated, 
respectively (Alizadeh et al). 
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                         3. AIMS AND OBJECTIVES 
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 The aim of this study is to  
1. Isolate Candida from diabetic patients with symptomatic candidiasis. 
2. Speciate the Candida isolates obtained from clinical specimens phenotypically. 
3. Study the prevalence of non- albicans Candida among the isolates. 
3. Assess the anti fungal susceptibility of the isolated species of Candida. 
4. Evaluate ERG11 expression among Fluconazole resistant isolates using molecular methods. 
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                4. MATERIALS AND METHODS 
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4.1 Study Period: 
This is a prospective cross sectional study undertaken over period of  one year from June 2017 – 
July 2018 
4.2 Study Place: 
This study was carried out in the Department of Microbiology, Department of Medicine and 
Department of Obstretics and Gynaecology –  Tirunelveli Medical College        
4.3.1 Study Group: 
Diabetic patients with symptomatic candidiasis were included in this study 
4.3.2 Inclusion Criteria: 
             Diabetic patients with symptomatic candidiasis 
4.3.3 Exclusion Criteria: 
o Patients who were not suffering from  diabetes 
o Pregnant women 
o Patients who were on cancer chemotherapy 
o Patients suffering from HIV/AIDS. 
o Patients who were on antibiotics 
o Patients who were catheterized. 
4.4 Ethical clearance  
The study was started after getting ethical committee clearance from the institution. 
4.5 Informed consent  
Informed consent was obtained from all patients included in the study. 
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4.6 Proforma: 
The proforma was filled with the details like name, age, sex, Fasting blood glucose levels , 
treatment status for diabetes and other parameters significant to the present study. 
4.7 Specimen Collection: 
 Vulvovaginal swabs were collected using cotton tipped swab. All swabs were 
immediately transported to the Microbiology Laboratory of the hospital for processing. 
 For urine specimen, the patients were instructed to collect 10 mL of a clean-catch 
midstream urine specimen into a sterile screw-capped wide-mouth container. The 
container was labeled with a sample number and date and time of collection, and was 
immediately delivered to the microbiology laboratory of Tirunelveli Medical College 
Hospital. 
4.8 Specimen Processing: 
Specimens collected were subjected to standard mycological procedures. 
4.8.1 Direct Microscopic examination: 
One swab was used for the direct microscopic examination by Gram stain. For each specimen , 
smears were made on a dry, clean glass slide, air dried and heat fixed . The fixed smears were 
stained by Gram staining method and observed under the oil immersion for the presence of gram 
positive budding yeast cells with or without pseudohyphae 
4.8.2 Culture on Sabourauds Dextrose Agar: 
The culture medium used was Sabourauds Dextrose Agar with pH 5.6.Second swab was 
inoculated immediately into the plates and incubated at 280C and 370C for 24-72 hours. Isolates 
were identified by colony morphology on SDA plates. Growth appeared in 2 to 3 days as 
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creamy, white pasty colonies .The microscopic morphology of the colony on Gram stain was 
noted. 
4.8.3 Species identification: 
Isolates were speciated based on the following tests: 
Germ Tube Test: 
 0.5ml of human serum was taken in a sterile test tube. 
 A small portion of an isolated colony of the yeast to be tested was inoculated into the 
human serum. 
 The test tube was incubated at 370C for two hours.  
 After two hours of incubation, a drop of the yeast serum suspension was placed on a 
microscopic slide , overlaid with a cover slip and examined for the presence of germ tube 
under lowpower microscope 
 If the test was positive within two hours, the isolate was considered as Candida albicans / 
Candida dubliniensis 
Growth at 42⁰ C: 
All germ tube positive isolates were subcultured on SDA and incubated aerobically at 420C, to 
distinguish between Candida albicans and Candida dubliniensis 
Candida albicans : Growth of candida present 
Candida dubliniensis : Scanty / Absent 
Corn Meal Agar (Dalmau Plate Culture Technique): 
 An isolated colony from the primary culture media was taken using a straight wire and 
inoculated into cornmeal agar plate by making three parallel lines about half an inch apart 
at an 450 angle to the culture media. 
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 A sterile cover slip was placed over the surface of the agar, covering a portion of the 
inoculated streaks. 
 Plate was incubated at 280C for 48 hours. 
 After 48 hours , the areas where the cuts into the agar made, were examined first under 
the low power objective and then under the high power objective for the presence of 
Hyphae - true or pseudohyphae, Blastoconidia, Arthroconidia and Chlamyoconidia 
Candida CHROM agar 
 Isolates were subcultured  on Sabourauds Dextrose agar prior to inoculation on 
chromogenic media. 
 A single yeast colony was streaked onto the plates. 
 Plates were incubated at 370 C in the dark. 
 The results were read after 48 hours and the colour of the colony was noted. 
 This helps in the presumptive identification of most commonly isolated Candida species 
especially Candida albicans, Candida tropicalis, Candida krusei. 
Candida albicans - Light green 
Candida tropicalis - Steel blue  
Candida krusei – Whitish Pink 
Candida parapsilosis - Purple 
Candida glabrata – Cream coloured 
Candida dubliniensis - Dark green 
Sugar Assimilation test: 
 A yeast suspension was made from a 24-48 hrs culture grown in a sugar free media, in to 
2 ml of Yeast Nitrogen base by adding heavy inoculums. 
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 The suspension was added to 18 ml of molten agar cooled to 45⁰  c and mixed well and 
the entire volume was poured in to a 90 mm sterile petri plate. 
 The plate was allowed to set at room temperature until the agar surface hardens. 
 With the help of sterile forceps, carbohydrate discs like glucose, sucrose, lactose, 
maltose, xylose and  trehalose were placed on the surface of the inoculated agar. 
 The plates were incubated at 300C for 48-96 hrs hr and were observed for the growth of 
yeast around the sugar discs, indicating assimilation of that particular carbohydrate. 
 Each Candida species utilizes specific carbohydrate substrate and the characteristic 
carbohydrate profiles were used to identify the species(Annexure )  
4.8.4 Antifungal Susceptibility testing: 
Antifungal susceptibility test for the Candida isolates was done by Disk Diffusion method 
according to The National Committee for Clinical Laboratory Standards (NCCLS) Method for 
Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline.NCCLS 
document M44-A 
Inoculum Preparation:   
 Inoculum was prepared by Direct Colony Suspension Method 
 All organisms are subcultured onto Sabourauds Dextrose agar to ensure purity and 
viability and incubated at 350C. 
 Inoculum was prepared by picking five distinct colonies of approximately 1 mm in 
diameter from the 24-hour-old culture of Candida species.  
 Colonies were then suspended in 5 mL of sterile 8.5 g/L NaCl; (0.85% saline) and the 
resulting suspension was vortexed for 15 seconds and its turbidity was adjusted visually 
by adding sufficient sterile saline or more colonies to adjust the transmittance to that 
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produced by a 0.5 McFarland standard to yield a yeast stock suspension of 1 x 106 to       
5 x 106 cells per ml which produced a semi-confluent growth with most Candida species 
isolates. 
Inoculation of Test Plates: 
 Within 15 minutes after adjusting the turbidity of the inoculum suspension, a sterile 
cotton swab was dipped into the suspension.  
 The swab was rotated several times and pressed firmly against the inside wall of the tube 
above the fluid level to remove excess fluid from the swab. 
 The dried surface of a sterile Mueller-Hinton + GMB agar plate was inoculated by evenly 
streaking the swab over the entire agar surface. This procedure was repeated by streaking 
two more times, rotating the plate approximately 60° each time to ensure an even 
distribution of inoculums and then the rim of the agar was swabbed. 
 The lid was left ajar for three to five minutes to allow for any excess surface moisture to 
be absorbed before applying the drug-impregnated disks. 
Application of Disks to Inoculated Agar Plates: 
 Antimicrobial disks were dispensed onto the surface of the inoculated agar plate and each 
disk was pressed down to ensure its complete contact with the agar surface. 
 The disks were placed individually so that they are no closer than 24 mm from center to 
center.  
 The plates were inverted and placed in an incubator set to 350C (± 20C) within 15 minutes 
after the application of discs 
 Candida albicans ATCC 90028 was used as the Quality control strain 
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Reading Plates and Interpreting Results: 
 Each plate was examined after 20 to 24 hours of incubation and the resulting zones of 
inhibition were uniformly circular with a semiconfluent growth. 
  The plate was held a few inches above a black, nonreflecting background illuminated 
with reflected light to measure the zone diameter to the nearest whole millimeter at the 
point at which there was a prominent reduction in growth.  
 Pinpoint microcolonies at the zone edge or large colonies within the zone were ignored 
and the zones were interpreted as per NCCLS document M44-A(Annexure) 
4.8 Detection of ERG11 Expression Using PCR: 
PCR Requirements: 
 PureFast® Bacterial/fungal DNA minispin purification kit -Lysozyme ,Lysozyme 
digestion buffer, Proteinase-K, Binding buffer, Wash Buffer-1, Wash Buffer-2, Spin 
columns with collection tube and elution buffer.  
 HELINI 2X ReD dye  
 ERG11 gene Primers were from HELINI Biomolecules, Chennai, India -5μl/reaction 
 2X Master Mix:  2U of Taq DNA polymerase, 10X Taq reaction buffer, 2mM MgCl2, 
1μl of 10mM dNTPs mix and Red Dye PCR additives. 
 Agarose gel electrophoresis consumables: Agarose, 50X TAE buffer (Tris base, acetic 
acid and EDTA), 6X gel loading buffer and Ethidium bromide were from HELINI 
Biomolecules, Chennai. 
PCR Product: 273bp 
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Candida DNA Purification: 
1. 1ml of culture centrifuged at 6000rpm for 5min and supernatant discarded 
2. Pellet was suspended in 0.2ml PBS. 
3. 180μl of Lysozyme digestion buffer and 20μl of Lysozyme [10mg/ml] added and incubated at 
370C for 15min. 
4. 400μl of Binding buffer, 5μl of internal control template and 20μl of Proteinase K added and 
mixed well by inverting several times and incubated at 560C for 15min. 
5. Then 300μl of Ethanol was added and mixed well. 
6. Then the entire sample was transferred into the PureFast® spin column and centrifuged for 1 
min, discarded the flow-through and placed the column back into the same collection tube. 
7. Added 500μl Wash buffer-1 to the PureFast® spin column. Centrifuged for 30-60 seconds and 
discarded the flow-through and placed the column back into the same collection tube. 
8. Added 500μl Wash buffer-2 to the PureFast® spin column. Centrifuged for 30-60 seconds and 
discarded the flow-through and then place the column back into the same collection tube. 
9. Discarded the flow-through and centrifuged for an additional 1 min. This step was done to 
avoid residual ethanol. 
10. Transferred the PureFast® spin column into a fresh 1.5 ml micro-centrifuge tube. 
11. Added 100μl of Elution Buffer to the center of PureFast® spin column membrane. 
12. Incubated for 1 min at room temperature and centrifuged for 2 min. 
13. Discarded the column and stored the purified DNA at -20°C. Quality and quantity of 
extracted DNA was checked by loading in 1% agarose gel and 5μl of extracted DNA was used 
for PCR amplification. 
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PCR Procedure: 
1. Reactions were set up as follows; 
Components Quantity 
 HELINI RedDye PCR Master mix 10μl 
 HELINI Ready to use - Primer Mix 5μl 
 Purified Purified DNA 5μl 
 Total volume 20μl 
2. Mixed gently and spun down briefly. 
3. Placed into PCR machine and programmed it as given in PCR setup 
PCR setup: 
Initial Denaturation: 95ºC for 5 min 
Denaturation: 94ºC for 30sec 
Annealing: 58ºC for 30sec 35 cycles 
Extension: 72ºC for 30sec 
Final extension: 72º C for 5 min 
Loading: 
1. Prepared 2% agarose gel. [2gm of agarose in 100ml of 1X TAE buffer] 
2. Ran electrophoresis at 50V till the dye reaches three fourth distances and observed the bands 
in UV Transilluminator. 
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Agarose gel electrophoresis: 
1. Prepared 2% agarose gel (2gm agarose in 100ml of 1X TAE buffer and melted using 
microoven) 
2. When the agarose gel temperature was around 60ºC, 5μl of Ethidium bromide was added.      
3. Poured warm agarose solution slowly into the gel platform. 
4. Kept the gel set undisturbed till the agarose solidified. 
5. Poured 1X TAE buffer into submarine gel tank. 
6. Carefully placed the gel platform into tank and maintained the tank buffer level 0.5cm above 
the gel. 
7. PCR Samples were loaded after mixed with gel loading dye along with 10μl HELINI 
100bp DNA Ladder. [100bp, 200bp, 300bp, 400bp, 500bp, 600bp, 700bp, 800bp, 900bp, 
1000bp and 1500bp] 
8. Ran electrophoresis at 50V till the dye reaches three fourth distance of the gel. 
9. Gel viewed in UV Transilluminator and observed the band pattern. 
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                                                5. RESULTS 
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            A total of 102 specimens were collected from  diabetic patients with symptomatic 
candidiasis. Out of these 102 specimens, 56 were vaginal specimens from diabetic females and 
46 were urine specimens from diabetic males. 
           From these samples, a total of 29 Candida isolates were obtained and then speciated based 
on germ tube test, sugar assimilation, Dalmau plate technique and CHROM agar. These Candida 
species were subjected to antifungal susceptibility testing by disc diffusion method using the 
following antifungal agents: Fluconazole, Voriconazole and Itraconazole. The isolates which 
were found to be resistant to Fluconazole were further subjected to ERG11 PCR. 
       Data collected were entered in Microsoft Excel and analysed using statistical analysis 
software Statistical Package for Social Services (SPSS) v.16. Appropriate statistics were 
calculated. p values <0.05 were statistically significant. 
5.1. Description of study Group: 
5.1.1. Age and gender distribution of the study population: 
 The mean age of the diabetic patients from whom Candida were isolated was 53.7 years 
with a SD of 12 years. The mean age of the male diabetic patients (61.8 years with SD 10 years) 
was significantly higher than that of female diabetic patients (47 years with SD 8.9 years) (p 
value < 0.001, Independent sample t test). 
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Table 1: Age and gender wise distribution of study group 
AGE (in 
years) 
Male patients with 
Diabetes 
Feale patients with 
Diabetes 
Total 
No. % No. % No % 
31 - 40 2 4.3 15 26.8 17 16.7 
41 - 50 5 10.9 24 42.9 29 28.4 
51 - 60 16 34.8 11 19.6 27 26.5 
61-70 11 23.9 6 10.7 17 16.7 
>70 12 26.1 - - 12 11.8 
TOTAL 46 100 56 100 102 100 
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Figure 1: Age wise distribution of female Diabetic 
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5.1.2. Symptoms of the study population: 
 The most common symptom of candidiasis among male diabetic patients was found to be 
dysuria (63%) and that among female diabetic patients was found to be vaginal discharge (66%) 
followed by pruritus and burning sensation. 
                                       Table 2: Symptoms of the study population 
Female Diabetic patients  Male Diabetic patients  
Symptoms        Frequency Symptoms Frequency 
Vaginal discharge 20 Dysuria 29 
Pruritis and Burning 
sensation 
26 Frequency and 
urgency 
11 
Vaginal discharge, Pruritis 
and Burning sensation 
10 Dysuria ,Frequency 
and urgency 
6 
Recurrence of symptoms 3   
4%
11%
35%
24%
26%
Figure 2: Age wise distribution of Male patients with 
Diabetes
31-40 yrs 41-50 yrs 51-60 yrs 61-70 yrs >70 yrs
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Figure 3: Distribution of female Diabetic patients based on their symptoms 
 
Figure 4: Distribution of male Diabetic patients based on their symptoms 
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5.1.3. Fasting blood glucose level of the study population: 
  None of the diabetic population among the study population had fasting blood 
glucose level under control (i.e. <126mg/dl). The mean fasting blood glucose level of the 
diabetic patients was found to be 157 mg/dl (SD 12 mg/dl). 
                         Table 3: Distribution of study group based on FBS level 
Fasting blood 
glucose level in 
mg/dl 
Female Diabetic 
patients (N = 56) 
Male Diabetic 
patients (N=46) 
Total (N=102) 
Frequency % Frequency % Frequency % 
131-140 10 17.86 - - 10 9.8 
141-150 18 32.14 7 15.22 25 24.5 
151-160 15 26.78 10 21.74 25 24.5 
161-170 10 17.86 20 43.48 30 29.4 
171-180 3 5.36 6 13.04 9 8.8 
>180 - - 3 6.52 3 2.9 
Mean FBS 152 mg/dl (SD – 11 
mg/dl) 
 
162 mg/dl (SD – 11 
mg/dl) 
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 Fasting blood glucose level showed a statistically significant relationship with the age of 
the diabetic patients. It could be seen from the means plot (below) that the FBS levels steadily 
increases with increase in age of the diabetic patients (p value <0.001, One way ANOVA). There 
exist a significant positive correlation between the age of the patient and FBS levels (see scatter 
plot).  
                 Figure 6: Means plot showing mean FBS levels among various age groups 
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Figure 5: Distribution of study group based on FBS levels 
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Figure 7: Scatter plot showing FBS levels among various age groups 
 
 
5.1.4. Treatment status of the study population: 
 Only 47% of the diabetic patients were on treatment. The mean age of the diabetic 
patients on treatment (62 years with SD 9.5 years) was found to be significantly higher than that 
of the diabetic patients who were not on treatment (46 years with SD 8.6 years) (p value < 
0.001).  
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Table 4: Distribution of Diabetic study group based on their treatment status for Diabetes 
Treatment 
status 
On treatment Not on 
treatment 
Test p value 
No. % No. % 
Male 
 
29 63 17 37 Chi square 
test, χ2 = 
8.593  
df = 1 
0.005 
(significant) 
Female 
 
19 34 37 66 
Total 48 47 54 53 
Mean age (in 
years) (SD) 
62 (9.5) 46 (8.6) Independent 
sample t test 
<0.001 
(significant) 
 
5.2. Isolation of Candida: 
5.2.1. Gram Staining: 
On gram staining, 19 smears were found to be  positive for Candida. Out of the 19 
positive smears, 15 were vaginal swab smears  and only 4 were urine smears. 5 smears were 
positive for budding yeasts with pseudohyphae, 14 for budding yeasts only and 83 were found to 
be negative. Nearly 27% of the vaginal swabs of the vaginal smears were positive for Candida 
on gram staining, whereas only 8.6% of the urine smears were positive for Candida on gram 
staining.  
                            
68 
 
Table 5: Gram stain results of vaginal and urine smears 
Smear Gram staining 
Budding yeasts with 
pseudohyphae 
Budding yeasts 
only 
Negative 
Vaginal swabs (n = 56) 3 (5.4%) 12 (21.4%) 41 (73.2%) 
Urine (n = 46) 2 (4.3%) 2 (4.3%) 42 (91.3%) 
Total (N = 102) 5 (4.9%) 14 (13.7%) 83 (81.4%) 
 
 
 
 
 
 
4% 4%
92%
Figure 9: Gram stain results of urine smeras of male Diabetic 
patients
Budding yeast cells with
pseudohyphae
Budding yeast cells only
Negative
5%
22%
73%
Figure 8 :Gram stain results of vaginal swab smears of 
female Diabetics
Budding yeast cells with pseudohyphae Budding yeast cells only Negative
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5.2.2. Culture: 
A total of 29 samples were found to be positive for Candida on culture. Around 41% of 
vaginal swabs were positive whereas only 13% of the urine samples were found to be positive 
for Candida by culture. 
Table 6: Culture results for Candida among the study group 
Smear Culture results 
Positive Negative 
Vaginal (n = 56) 23 (41.1%) 33 (58.9%) 
Urine (n = 46) 6(13%) 40(87%) 
Total (N = 102) 29 (28.4%) 73 (71.6%) 
 
Figure 10: Prevalence of VVC and Candiduria among Diabetic females and males 
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5.2.3. Culture results Vs treatment status: 
 The culture results for Candida did not show any significant association with age and 
fasting blood glucose levels of the diabetic patients. However, there is significant relationship 
between the culture results and the treatment status of the patients. Nearly 37% of the diabetic 
patients who were not under treatment had candidiasis, whereas only 19% of the diabetic patients 
on treatment had candidiasis.                                
Table 7: Treatment for Diabetes Vs Candidiasis 
Treatment 
status 
Culture Total Test p value 
Positive Negative 
On 
treatment 
9 (18.8%) 39 (81.3%) 48 Chi square 
test, χ2 value = 
4.176 
df = 1 
0.04 
(significant) 
Not on 
treatment 
20 (37%) 34 (63%) 54 
Total 29 73 102 
 
 
On treatment Not on treatment
26.32
48.65
73.68
51.35
Figure 11: Correlation of Vulvovaginal candidiasis 
with treatment status
CulturePositives Culture negatives
71 
 
 
5.2.4. Gram stain Vs Culture 
 Culture results showed that Candida was isolated from nearly 28.4% of the 
specimens collected from diabetic patients, whereas gram staining found only 18.6% of the 
specimens to be positive for Candida.  
Table 8: Isolation of Candida: Gram stain Vs culture 
Gram stain Culture Total 
(N=102) Positive Negative 
Positive 19 (65.5%) 0 19 
Negative 10 (34.5%) 73 (100%) 83 
Total 29 73 102 
                       
13.79 11.76
86.21 88.24
On treatment Not on treatment
Figure 12: Correlation of candiduria with treatment 
status
CulturePositives Culture negatives
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           The above table shows that only 65.5% of specimens found to be culture positive were 
identified as positive for Candida on gram staining. Whereas, all specimens found to be culture 
negative were found to be negative for Candida on gram staining. 
This shows that the gram staining is highly specific (100%) and only 65.5% sensitive in 
isolating Candida. 
Figure 13: Gram stain Vs Culture for detection of Candida among vaginal samples 
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Figure 14: Gram stain Vs Culture for detection of Candida among urine samples 
 
Table 9: Comparison of culture positivity with FBS levels among Diabetics 
 
Fasting blood 
glucose level in 
mg/dl 
 
Vulvovaginal candidiasis 
 
Candiduria 
Culture 
Positives 
Culture 
negatives 
Culture 
Positives 
Culture 
negatives 
130-140 4 (40%) 6 (60%) - - 
141-150 6 (33.3%) 12 (66.7%) - 7 (100%) 
151-160 8 (53.3%) 7 (46.7%) - 10 (100%) 
161-170 4 (40%) 6 (60%) 4 (20%) 16 (80%) 
171-180 1 (33.3%) 2 (66.7%) 2 (33.3%) 4 (66.7%) 
>180 - - - 3 (100%) 
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The above table shows that that 66.7% of female diabetics with the FBS range of 141-150mg/dl 
and 171-180mg/dl were culture negatives in this study. Majority (53.3%) of culture positives 
were in the FBS range of 151-160mg/dl. In case of diabetic males, only 33.3% and 20% of those 
with the FBS range of 171-180mg/dl and 161-170mg/dl respectively had candiduria and the rest 
were culture negatives. 
5.3. Speciation of Candida: 
 Speciation of Candida was done by using CHROM agar, Dalmau plate technique, Germ 
tube test and sugar assimilation tests.38% of the culture positive isolates were found to be 
Candida albicans. Remaining 62% were non-albicans Candida which included C.tropicalis 
(24%), C.parapsilosis (10.3%), C.glabarata (20.7%) and C. krusei (7%). 
Table 10: Distribution of Candida species among male and female diabetics 
Species Vulvovaginal 
candidiasis 
Candiduria Total 
No. % No. % No % 
Candida albicans 9 39.1 2 33.3 11 37.9 
Candida tropicalis 6 26.1 1 16.7 7 24.1 
Candida glabrata 4 17.4 2 33.3 6 20.7 
Candida parapsilosis 2 8.7 1 16.7 3 10.3 
Candida krusei 2 8.7 - - 2 6.9 
Total 23 100 6 100 29 100 
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5.4. Anti Fungal Susceptibilty: 
All the 29 Candida isolates were subjected to antifungal susceptibility testing by disc diffusion 
method using Fluconazole,Voriconazole and Itraconazole. Highest level of sensitivity (100%) 
was seen for Itraconazole followed by Voriconazole. Highest level of resistance (17.4%) was 
seen against Fluconazole. All the isolates were found to be sensitive to Itraconazole. 28 isolates 
were sensitive to Voriconazole and one isolate was susceptible dose dependent to Voriconazole. 
25%
25%
50%
Figure 17 : Distribution of non albicans candida  
among  Candiduria
Candida tropiclais
Candida parapsilosis
Candida glabrata
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 Among the 6 Candida isolates obtained from candiduria , 4(66.7%) were sensitive 
and 2(33.3%)  were Dose dependent susceptible to Fluconazole. All the 6 isolates were sensitive 
to both Itraconazole and Voriconazole. 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Fluconazole Voriconazole Itraconazole
Figure 18: Antigungal susceptibility pattern among isolates from 
Vulvovaginal candidiasis
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Figure 19: Antigungal susceptibility pattern among isolates from 
Candidiuria
Sensitive isolates Susceptible dose dependent isolates
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5.4.1. Fluconazole resistance Vs Candida species 
 
Table 11: Fluconazole susceptibility pattern of isolates of Vulvovaginal candidiasis 
 
Candida albicans Non albicans candida
66.7
21.43
22.2
42.86
11.1
21.43
14.28
Figure 20: Fluconazole susceptibility pattern of Candida albicans 
and non- albicans Candida isolates of Vulvovaginal candidiasis
Sensitive isolates Susceptible dose dependent isolates
Resistant isolates Intrinsically resistant isolattes
Candida species Sensitive 
Susceptible Dose 
Dependent 
Resistant 
Candida albicans 6(66.7%) 2(22.2%) 1(11.1%) 
Candida tropicalis 2(33.3%) 1(16.7%) 3(50%) 
Candida glabrata - 4(100%) - 
Candida parapsilosis 1(50%) 1(50%) - 
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5.4.2. Fluconazole resistance Vs Treatment status and FBS 
 Resistance to Fluconazole was high among those who were not on treatment. None of the 
diabetic patients on treatment was found to be resistant to Fluconazole, whereas nearly 17.4 % of 
the isolates from patients not on treatment were found to be resistant to Fluconazole     (p value – 
0.40, Fishers exact test). Resistance to Fluconazole did not show any significant relationship with 
fasting blood glucose (p value – 0.36, Independent sample t test).
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The 4 Fluconazole resistant isolates were isolated from patients who were not on any form of 
treatment for diabetes. Among the 4  isolates , one of them was Candida albicans (25%) and the 
rest were  Candida tropicalis (75%). 
5.5 Detection of Mechanism of Resistance Using PCR: 
Table 12: ERG11 PCR in Fluconazole resistant isolates 
Fluconazole resistant 
isolates(n=4) 
PCR 
Positives Negatives 
Candida albicans(n=1) - 1 (100%) 
Candida tropicalis(n=3) 1(33%) 2 (67%) 
 
 
 
 
 
 
 
 
 
33
100
67
Candida albians Candida tropicalis
Figure 23: PCR results in Fluconazole resistant isolates 
Positive Negative
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The four Fluconazole resistant isolates were subjected to molecular methods for detection of the 
mechanism of azole resistance using PCR done to detect the point mutation C1214T and one was 
found to be positive. Increased ERG11 gene expression due to point mutation results in the 
production of a large amount of 14 α-lanosterol demethylase, favoring the continuous synthesis 
of ergosterol and the maintenance of cell integrity which in turn allows the fungus to resist the 
action of the drug.  
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 Candidiasis has emerged as an alarming opportunistic infection with an increase in a number of 
patients among the diabetics who have immune dysfunction. The intensity of infection is more 
severe and the response to therapy is slow in diabetic patients. Over the last decade, non-albicans 
Candida associated with human infections have increased and in recent times have developed 
resistance to anti‑ fungal agents, in particular to the azole compounds. The present study was 
carried out to determine the relative contribution of C. abicans and non-albicans species in 
diabetic patients with symptomatic candidiasis , their antifungal susceptibility profile and role of 
ERG11 expression in azole resistance. 
In our study, 102 specimens were collected out of which 56 were vaginal specimens from 
diabetic females and 46 were from urine specimens from diabetic males. The mean age of the 
diabetic patients from whom specimens were collected in our study was 53.7 years with a SD of 
12 years. The mean age of the male diabetic patients was 61.8 years with a SD of 10 years 
among which the majority (34.8%) of them were between 51-60 years of age (Table 1 and 
Figure 1). The female diabetic patients in our study had a mean age of 47 years (with SD 8.9 
years) and 42.9 % fell between 41-50 years of age (Table 1 and Figure 2). The lower mean age 
in females may be due to the fact that most of the patients attending the outpatient department 
belong to the reproductive age group. 
In our study, the chief complaint among the symptomatic female diabetic patients was vaginal 
discharge which accounts for about 46.4% followed by pruritis and burning sensation (35.7%). 
These results were in accordance with the study by Rathod et al which showed a higher rate of 
complaints of vaginal discharge (31%) followed by pruritis (29%). Both Vaginal discharge and 
pruritis with burning sensation were present in 17.9% of the diabetic females. Out of the 56 
diabetic females, only three (5.4%) complained of recurrence of symptoms within 1year (Table2 
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and Figure 3). The positive predictive values of these symptoms for predicting vulvovaginal 
candidiasis were low. A minority of women with these symptoms were subsequently diagnosed 
with vulvovaginal candidiasis (53.85%, 25%and 50% respectively). The low positive predictive 
value of symptoms indicate that the patients should not be treated based on symptoms alone 
which may inadvertently leads to treatment of patients without arriving at a correct diagnosis. 
Among the 46 symptomatic diabetic males, 63 % complained of dysuria followed by frequency 
with urgency of micturition (23.95%). All these symptoms were present in 13% of the diabetic 
males (Figure 4). All these symptoms were consistent with the symptoms of Candida cystitis as 
shown in studies by Achkar et al and Bukhary ZA et al. 
The mean fasting blood glucose level of the diabetic patients was found to be 157 mg/dl (SD 12 
mg/dl). Table 3 shows that the mean fasting blood glucose in diabetic males was 162mg/dl with 
a SD of 11 mg/dl and that of diabetic females was 152mg/dl with a SD of 11mg/dl. This 
disparity may be due to difference in the age groups taken into study, their dietary habits, 
physical activity index, patient education and adherence to treatment regimen. 
Table 3 and Figure 5 shows that majority (32.14%) of diabetic females had their fasting blood 
glucose levels between 141-150mg/dl and 43.48% of the diabetic males had a fasting glucose 
level in the 161-170mg/dl range. Figure 6 and 7 shows that the FBS levels steadily increases 
with increase in age of the diabetic patients and there is a significant positive correlation between 
the age of the patient and FBS levels.  
But studies by De et al and Eid M et al which showed that younger subjects showed a poor 
glycemic control with high HbA1C levels. Both these studies also show that patients with 
recently diagnosed diabetes (duration of disease < 5 years) had the best glycemic control. The 
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discordance between the studies may be attributed to the fact that the duration of diabetes, 
dietary habits and physical status are not included in our study. 
The mean age of the diabetic patients on treatment (62 years with SD 9.5 years) was found to be 
significantly higher than that of the diabetic patients who were not on treatment (46 years with 
SD 8.6 years). Among the 47% who were on treatment, 63% were males and 34% were females 
(Table 4). This difference in treatment status between males and females may be attributed to the 
fact that Diabetes is still considered a social stigma among some females in rural India and they 
have low awareness about their disease, its complications, adherence to medication and other self 
care practices. 
In our study only 19 (18.6%) of smears were found to be positive for Candida by gram staining. 
Of these, 15 were vaginal smears and only 4 smears were from urine. Table 5 and Figure 8 
shows that 73.2% of the vaginal smears were negative on gram staining and only 26.8% were 
found to be positive which is higher than that of the study by Vijaya et al which showed a 
positivity of only 7.3%.Among the positives, 21.4% showed budding yeast cells and 5.4% 
showed budding yeast cells with pseudohyphae. Urine smears for Candida only showed a 
positivity rate of 8.6% .Figure 9 shows that both the budding yeast cells and budding yeast cells 
with pseudohyphae were present in 4.3% of the total urine smears.  Gram stain is a valuable 
method in rapid accurate diagnosis of symptomatic VVC and even superior to culture as it 
demonstrates the invasive forms of the yeast. 
 Culture positivity for Candida was found in 41.1% of diabetic females in our study (Table 6 and 
Figure 10). Studies by Goswami et al and Shrivastav et al showed a culture positivity of 46% 
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and 47.5% respectively. Peer et al reported a prevalence rate of 35.5% and Faraji et al. reported a 
prevalence of vulvovaginal candidiasis  as 20% among diabetic women in their studies. 
Table 6 and Figure 10 also shows that Candida was isolated by culture from 13% of urine 
samples from diabetic males which is lower than that of the study by Yismaw et al which 
showed a prevalence of 17.1% in symptomatic diabetics. Pandey et al reported  a higher 
prevalence of candiduria (43.75%  ) in his study. Similarly, Goyal et al and  Zarei et al   reported 
candiduria in 2.36% and 16.5%, of their study populations, respectively. 
The culure positivity for Candida did not show any significant association with age and fasting 
blood glucose levels of the diabetic patients but nearly 37% of diabetics who were not any 
treatment had candidiasis whereas candidiasis was present only in 18.8% diabetics who were on 
treatment (Table 7) which shows there is a significant relationship between the occurrence of 
candidiasis and the treatment status of patients for diabetes. Figure 11 shows that 26.32% of 
diabetic females who were on treatment and 48.65% who were not on any form of treatment for 
diabetes suffered from vulvovaginal candidiasis respectively. Figure 12 shows that candiduria 
was present in 13.79% who were on treatment for diabetes but only 11.76% of males with 
untreated diabetes had candiduria. 
28.4% of the specimens were found to be positive for Candida by culture whereas only 18.6% of 
the samples were found to be positive by gram staining. Table 8 shows that only 65.5% of 
culture positives were also found to be positive by gram staining. Figure 13 and 14 shows the 
lower sensitivity of gram stain compared to culture in detecting Candida. Even though gram 
staining is highly specific in our study, it is only found to be 65.5% sensitive by our study.  
Lower sensitivity of gram stain compared to culture was showed in studies by Vijaya et al 
(41.41%), Bello et al (70%) and Goswami et al(77%).Though gram stain can detect the invasive 
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form of the yeast , given the fact that C. glabrata and some Candida albicans mutants cannot 
produce hyphae but clearly can cause candiduria  confirming that the presence of hyphae is not a 
valid marker for infection. In addition its low sensitivity could also restrict its use in routine 
practice. So a combination of culture and gram stain is the ideal approach for the diagnosis of 
candidiasis. 
Table 9 shows that 66.7% of female diabetics with the FBS range of 141-150mg/dl and 171-
180mg/dl were culture negatives in our study. Majority (53.3%) of culture positives were in the 
FBS range of 151-160mg/dl. In case of diabetic males, only 33.3% and 20% of those with the 
FBS range of 171-180mg/dl and 161-170mg/dl respectively had candiduria and the rest were 
culture negatives. 
The speciation of the isolates was done by using CHROM agar, Dalmau plate technique, Germ 
tube test and Sugar assimilation tests. CHROM agar is a simple and rapid test for speciation and 
has a additional advantage of identification of Candida from mixed cultures while sugar 
assimilation test takes upto 48-96 hours. The species obtained from vulvovaginal candidiasis 
were Candida albicans (39.1%), Candida tropicalis (26.1%), Candida glabrata (17.4%), 
Candida parapsilosis (8.7%) and Candida krusei (8.7%). The distribution of Candida species 
isolated from diabetic patients with vulvovaginal candidiasis showed a majority of Candida non 
albicans which was 61.9% (n=14) whereas Candida albicans isolates constituted only 39.1% 
(n=9) as shown in Table 10 and Figure 15. Among the non albicans Candida (n=14), Candida 
tropicalis was the commonest isolate 42.85% (n=6) in our study as shown in Figure 16 followed 
by Candida glabrata 28.57% (n=4), Candida parapsilosis 14.29% (n=2) and Candida krusei 
14.29% (n=2)(Figure 16). 
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Shrivastav et al isolated a majority of non-albicans Candida isolates in his study and overall 12 
(21.1%) Candida albicans, 15 (26.3%) Candida glabrata, 24 (42.1%) Candida krusei and 6 
(10.5%) Candida tropicalis were isolated. In symptomatic group of diabetic patients Candida 
albicans was predominant as 10 (17.5%) followed by Candida glabrata 8 (14%), while in 
asymptomatic group of patients Candida krusei 19 (33.3%) was predominant. 
 Candida glabrata was isolated  in 68 (61.3%) , Candida albicans in 32 (28.8%) and Candida 
tropicalis in 4(3.6%) of diabetic patients with vulvovaginal candidiasis by Ray D et al. Study by 
Faraji R et al showed that the predominant Candida species isolated in diabetics with vulvo-
vaginal candidiasis were Candida glabrata (39%), Candida albicans (26%)  and  Candida 
tropicalis (17%). 
Among isolates obtained from candiduria, only 33.3% isolates were Candida albicans and the 
rest were non-albicans Candida. As shown in Figure 17, 50% of isolates were Candida glabrata 
and the rest was contributed equally by Candida tropicalis and Candida parapsilosis. 
Study by Pandey et al showed that the major Candida species isolated were Candida tropicalis 
34% (17) followed by C. albicans 30% (15), C. parapsilosis 16% (8), C. glabrata 14% (7) and 
C. krusei 6% (3) which indicated that non- albicans Candida  were  emerging in urine of diabetic 
patients and Falhati M et al isolated Candida glabrata (n=19, 50%), C. albicans (n=12, 31.6%), 
C. krusei (n=4, 10.5%), C. tropicalis (n=2, 5.3%), and C. kefyr (n=1, 2.6%) from urine of 305 
diabetic outpatients. In both these studies majority of the isolates were non-albicans Candida 
species. 
Fluconazole is still considered the first-line treatment for Candida infections because it offers the 
advantages of oral formulations, favorable bioavailability, and low level of toxicity. The 
Fluconazole resistance of Candida species has been increasingly reported in the past decade. The 
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antifungal susceptibility testing done by Kirby-Bauer disk diffusion method on isolates from 
Vulvovaginal candidiasis showed that 39.1% (n=9) were sensitive, 34.8% (n=8) were susceptible 
dose dependent (SSD) and 17.4% (n=4) were resistant to Fluconazole in our study. Candida 
krusei which constituted 8.7% (n=2) of the isolates were considered resistant as they are 
intrinsically resistant to Fluconazole. 28 (95.7%) isolates were sensitive to Voriconazole and 
only one isolate (4.3%) which was Candida krusei showed intermediate resistance. All the 
isolates were sensitive to Itraconazole (Figure 18). 
Study by Kalaiarasan et al showed that 38 isolates (74.5%) were susceptible, 8 (15.7%) isolates 
were resistant and 5 (9.8%) isolates were S-DD to Fluconazole and all Candida species were 
found susceptible to Voriconazole. Fluconazole was found to be  sensitive in 36 (33.3%) 
patients, SDD in 5 (4.6%)  patients and resistant in 67 (62%) of patients with VVC in a study by 
Khan M et al and 64% isolates were found to be sensitive, 16% were SSD and 20% were found 
to be resistant by Khadka S et al.  
The increased resistance and  dose dependent susceptibile isolates in our study compared to the 
above studies  may be attributed to the presence of large number of Candida glabrata and 
Candida tropicalis in a small number of isolates.  
Among the 6 isolates from candiduria, 66.7% (n=4) were sensitive and 33.3% (n=2) were 
susceptible dose dependent (SSD) to Fluconazole (Figure 19) and the 2 susceptible dose 
dependent  isolates were found to be Candida glabrata. All the isolates were sensitive to both 
Voriconazole and Itraconazole in our study. Yashavanth et al noted that among 33 candiduria 
isolates in his study 66.66% were susceptible, 9.1% were SSD and 24.24% were resistant (which 
also include Candida krusei) to Fuconazole and 72.72% were susceptible, 9.1% were SSD and 
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18.18% were resistant  to Voriconazole .The above study also showed that only 66.6% of NAC 
were susceptible while 80% of Candida albicans were sensitive to Fluconazole. A study by 
Datta P et al showed that 62.7% candiduria isolates were resistant to Fluconazole. 
Among the Candida albicans isolates, 66.7% were sensitive, 22.2% were susceptible dose 
dependent and only 11.1% were resistant to Fluconazole whereas among NAC species only 
21.43% were sensitive, 42.86% were susceptible dose dependent, 21.43% were resistant and the 
rest were intrinsically resistant to Fluconazole. 33.3%, 16.7% and 50% of Candida tropicalis 
isolates were sensitive, SDD and resistant to Fluconazole respectively. All the isolates of 
Candida glabrata were reported as SDD as they cannot be reported sensitive to Fluconazole as 
per CLSI guidelines. Among the Candida parapsilosis isolates half were sensitive and the rest 
were SDD to Fluconazole. Table 11 and Figure 20 shows that majority of the SDD and resistant 
isolates were non-albicans Candida compared to Candida albicans. Among 17.4% of  
Fluconazole resistant isolates, 75% were Candida tropicalis and 25% were Candida albicans. 
However in a study done by Mohanty et al in 2006, none of the isolates were resistant to 
Fluconazole while 30% were found to be susceptible dose dependent. The majority of the SSD 
isolates were Candida glabrata which is similar to the findings in our study. The finding in our 
study is contrary to the study by Khan M et al which showed that Fluconazole was sensitive in 
37.7% , SDD in 8.8%  and resistant in 53.3% of Candida albicans isolates where as only 38.8% 
of C. tropicalis were resistant and the rest were sensitive to Fluconazole.37.5% of Candida 
glabrata isolates were found to be sensitive, while the rest were resistant to Fluconazole. 
 
But a study by Deorukhkar et al  showed that Fluconazole resistance was more common in C. 
tropicalis (29.5%), C. glabrata (27.3%) and C. kefyr (25%) isolates. 12.7% of  C. glabrata 
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isolates were dose dependent susceptible to Fluconazole. The higher Fluconazole resistance 
among Candida tropicalis isolates noted in the study by Deorukhkar et al is similar to the results 
obtained in our study. 
. 
Figure 21 shows that none of isolates from the diabetic patients on treatment were found 
resistant whereas 17.4% of isolates from untreated diabetes were found to be resistant to 
Fluconazole. No significant relationship was found between Fluconazole resistance and fasting 
blood glucose levels as shown in Figure 22. 
In one study, one Candida tropicalis isolate which was resistant to Fluconazole was found to be 
positive by PCR among the four tested resistant isolates (Table 12 and Figure 23). Although 
ERG gene is present in all species of Candida, the primer used in this study was designed to 
detect C1214T point mutation within the gene that leads to S405F aminoacid substitution as 
shown by Kelly et al, Pam et al and Perea et al, which was associated with resistance hence the 
detection of gene in some isolates and not in others. Point mutation in the ERG gene results in 
ERG11 over expression which in turn results in increased ergosterol synthesis ultimately 
counteracting the mechanism of action of azoles. 
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102 samples were collected in this study conducted in Tirunelveli Medical college,Tirunelveli 
from the period of  June 2017 to July 2018 of which 56 were vaginal specimens from diabetic 
females and 46 urine samples were collected from diabetic males. 
 The mean age of the diabetic patients from whom specimens were collected in this study 
was 53.7 years with a SD of 12 years. 
 The chief complaint among the symptomatic female diabetic patients was vaginal 
discharge (46.4%) and that of symptomatic diabetic males was dysuria (63%).Recurrent 
episodes were present in 5.4% of diabetic females.  
 There was a significant positive correlation between the age of the patient and FBS levels 
in this study. 
  The mean age of the diabetic patients on therapy for diabetes was found to be 
significantly higher than that of the diabetic patients who were not on treatment. Among 
the 47% who were on treatment, 63% were males and only 34% were females. 
 18.6% and 28.4% of the specimens were found to be positive for Candida by gram 
staining and fungal culture respectively. Gram stain is positive in only 65.5% of culture 
positives. 
 41.1% of diabetic females had Vulvovaginal candidiasis whereas only 13% of diabetic 
males had candiduria in this study. 
 The culture positivity for Candida did not show any significant association with age and 
fasting blood glucose levels of the diabetic patients but there is a significant relationship 
in this study between the occurrence of candidiasis and the treatment status of patients for 
diabetes. 
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 The isolates obtained from vulvovaginal candidiasis were Candida albicans (39.1%), 
Candida tropicalis (26.1%), Candida glabrata (17.4%), Candida parapsilosis (8.7%)  
and  Candida krusei (8.7%) and among candiduria isolates , only 33.3% isolates were 
Candida albicans and the rest were non-albicans Candida. 
 The antifungal susceptibility testing of isolates from vulvovaginal candidiasis shows that 
39.1% were sensitive, 34.8% were susceptible dose dependent (SSD) and 17.4% were 
resistant to Fluconazole while most of the isolates were sensitive to Voriconazole and all 
the isolates were sensitive to Itraconazole. 
  Candiduria isolates showed 66.7% susceptibility and 33.3% dose dependent 
susceptibility to Fluconazole and 100% susceptibility to Voriconazole and Itraconazole. 
 Among 17.4% of Fluconazole resistant isolates, 75% were Candida tropicalis and 25% 
were Candida albicans. No significant relationship was found between Fluconazole 
resistance and fasting blood glucose levels in this study. 
 Only one isolate was positive for PCR done to indirectly detect ERG11 overexpression 
among the four Fluconazole resistant isolates. 
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                                           8. CONCLUSION  
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The present study demonstrated the importance of species identification and susceptibility testing 
for antifungals in Candida isolated from diabetic patients as uncontrolled diabetes mellitus 
causes metabolic alterations such as increased levels of glycogen, which can significantly 
increase colonization and infection by Candida. 60.9 % of  non-albicans Candida were isolated 
in this study, among which only 21.4 % of the isolates were sensitive to  Fluconazole that are 
generally used for the management of Vulvovaginal candidiasis. Isolation of non-albicans 
Candida  have clinical implication due to their reduced susceptibility to various antifungals, thus 
highlighting the importance of isolation, species identification and antifungal susceptibility of 
Candida prior to initiation of therapy for proper selection of antifungal agent. The judicious use 
of antifungal agents is very important for the prevention of emergence and spread of drug 
resistant Candida species. 
This study indicates that non- albicans Candida are emerging as a cause of candiduria in diabetic 
patients and its isolation from clinical specimens can no longer be ignored as nonpathogenic 
isolate nor can it be dismissed as a contaminant. The emergence of non-albicans Candida 
isolates increases the need for evaluation of urine samples of diabetic patients and prescription of 
appropriate antifungal therapy. 
 Antifungal susceptibility testing should be used to calculate clinical response and accordingly 
local antibiograms can aid in empirical assortment of antifungals, guiding options for long-term 
therapy and are meant for alternative regimens in testing of isolates from recurrent infections. 
Alteration in sterol biosynthesis, analysis of expression level of ERG11 gene and analysis of 
gene sequences can be further investigated in clinical isolates of Fluconazole-resistant Candida 
species. Further studies are required to explore the molecular mechanisms that could be targeted 
to control Fluconazole resistance. 
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                                           10.ANNEXURE 
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I - PROFORMA 
PROFORMA 
S.No:                                                                                                       OP No. 
Name of the patient :  
Age :              Sex : 
Address : 
 Compliants:  
 Pruritis / Vaginal discharge/ Burning micturition 
Dysuria/Frequency/Urgency 
Past History : 
H/o similar complaints in the past : Yes/No 
No. of episodes: 
Laboratory Investigations : 
FBS level-  
Mycological Investigations 
Specimen – Vaginal Swab/Urine 
Microscopy 
Gram stain : 
Culture on SDA 
Colony morphology- 
Gram stain- 
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Speciation: 
Culture on CHROM agar- 
Germ tube test- 
Growth on Cornmeal agar- 
Sugar assimilation test: 
Sugars Glucose  Lactose  Maltose    Sucrose Trehalose Xylose 
Interpretation       
 
Antifungal Susceptibility testing: 
Antifungal discs Fluconazole(25µg) Voriconazole(1µg) Itraconazole 
Interpretation    
 
ERG PCR: 
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                                             II – PREPARATION OF MEDIA 
     
1. Sabouraud’s Dextrose Agar : 
Composition 
 Ingredients                Gms / Litre  
Dextrose (Glucose)    40.000  
Mycological peptone 10.000  
Agar                           15.000  
65.0 grams of the dehydrated media was suspended in 1000 ml of distilled water and boiled  to 
dissolve the medium completely. Media was sterilized by autoclaving at 15 lbs pressure (121°C) 
for 15 minutes. Media was cooled to 45-50°C and then poured into sterile Petri plates. Final pH 
was adjusted to 5.6±0.2  
 
2. HiCrome  Candida Differential Agar : 
Composition 
Ingredients                     Gms / Litre  
Peptone, special             15.000 
 Yeast extract                   4.000  
Dipotassium hydrogen     1.000 
 phosphate 
Chromogenic mixture      7.220 
 Chloramphenicol            0.500  
Agar                                15.000  
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42.72 grams of the dehydrated media was suspended in 1000 ml of distilled water and boiled to 
dissolve the medium completely as the media should not be autoclaved. Media was cooled to 45-
50°C and then poured into sterile petri plates. Final pH was adjusted to 6.3±0.2. 
 
3. Corn meal agar: 
Composition      
 Ingredients      Gms / Litre 
 Corn meal         50.000 
 Agar                   15.000 
 17 grams of the dehydrated media was suspended in 1000 ml of distilled water and boiled to 
dissolve the medium completely. Sterilized the medium by autoclaving at 15 lbs pressure 
(121°C) for 15 minutes. Media cooled to 45-50°C  and then poured into sterile Petri plates. Final 
pH was adjusted to 6.0±0.2. 
 
4. Yeast Nitrogen Base Agar: 
Composition  
Ingredients                           Gms / Litre  
Part A   
 Agar                                       40.000  
Part B  
Ammonium sulphate              5.000 
 L-Histidine hydrochloride     0.010 
 DL-Methionine                      0.020  
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DL-Tryptophan                       0.020  
Biotin                                      0.000002 
 Calcium pantothenate            0.0004 
 Folic acid                               0.000002  
Inositol                                    0.002  
Niacin                                     0.0004 
 p-Amino benzioc acid           0.0002  
Pyridoxine hydrochloride      0.0004  
Riboflavin (Vitamin B2)        0.0002  
Thiamine hydrochloride         0.0004 
 Boric acid                              0.0005 
 Copper sulphate                     0.00004  
Potassium iodide                     0.0001  
Ferric chloride                         0.0002  
Manganese sulphate                0.0004  
Sodium molybdate                   0.0002 
 Zinc sulphate                           0.0004  
Monopotassium phosphate       1.000  
Magnesium sulphate                 0.500  
Sodium chloride                        0.100 
 Calcium chloride                      0.100  
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40 grams of Part A was suspended in 900 ml of distilled water and boiled to dissolve the medium 
completely. Media was sterilized by autoclaving at 15 lbs pressure (121°C) for 12 minutes. 
Media was cooled to 50°C and aseptically admixed with sterile part B solution and then the 
plates are poured. Final pH was adjusted to 5.4±0.2 
 Part B was prepared in 10x strength by suspending 6.75 grams in 100 ml of distilled water and 
warmed to dissolve the medium completely. Sterilized the medium by filtration and was kept 
refrigerated until use. 
 
5. Mueller Hinton Agar, 2% Glucose with Methylene blue agar: 
Composition 
 Ingredients                                 Gms / Litre  
Beef infusion                                  300.000  
 Casein Acid Hydrolysate               17.500 
 Starch                                             1.500  
Glucose                                           20.000 
 Methylene blue                              0.0005  
Agar                                                17.000 
 58 grams of dehydrated media was suspended in 1000 ml of  distilled water and boiled  to 
dissolve the medium completely. Media was sterilized by autoclaving at 15lbs pressure (121°C) 
for 15 minutes. Media was cooled to 45-50°C  before pouring into petri plates. Final pH adjusted 
to 7.3±0.1. 
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6. McFarland 0.5 Turbidity standard 
 Prepare this turbidity standard by adding 0.5ml of 1.175% BaCl₂  to 99.5ml of 1% 
H₂ SO4 with constant stirring to maintain a suspension. 
 Verify the correct density of the turbidity standard by using a spectrophotometer. The 
absorbance at 625nm should be 0.08 to 0.10 for the 0.5 McFarland standard 
 Distribute 4 to 6ml into screw capped tubes and tightly seal these tubes and store them in 
the dark at room temperature. 
 Vigorously agitate this turbidity standard on a mechanical vortex just before use. 
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III – INTERPRETATION TABLES 
1.Sugar Assimilation Pattern: 
Candida Species Glucose  Lactose Maltose Sucrose Xylose  Trehalose 
C. albicans + + + + + + 
C. tropicalis + - + + + + 
C. parapsilosis + - + + + + 
C. glabrata + - - - + + 
C. krusei + - - - + - 
 
2. Interpretation of zone diameters in disk diffusion method as per NCCLS M44 A2-2009 
for Fluconazole : 
Candida species Interpretation of Zone diameters for Fluconazole (25µg) 
Susceptible Susceptible Dose 
Dependent(SDD) 
Resistant 
C. albicans ≥ 17mm 15-16mm ≤ 13mm 
C. tropicalis ≥ 17mm 15-16mm ≤ 13mm 
C. parapsilosis ≥ 17mm 15-16mm ≤ 13mm 
C. glabrata - ≥ 15mm ≤ 14mm 
C. krusei - - - 
 
 
 
 
119 
 
3. Interpretation of zone diameters in disk diffusion method as per NCCLS M44 A2-2009 
for  Voriconazole: 
Candida species Interpretation of Zone diameters for Voriconazole (1µg) 
Susceptible Intermediate Resistant 
C. albicans ≥ 17mm 15-16mm ≤ 14mm 
C. tropicalis ≥ 17mm 15-16mm ≤ 14mm 
C. parapsilosis ≥ 15mm 13-14mm ≤ 12mm 
C. glabrata - - - 
C. krusei ≥ 15mm 13-14mm ≤ 12mm 
 
 
4. Interpretation of zone diameters in disk diffusion method for Itraconazole: 
Interpretation of Zone diameters for Itraconazole (10µg) 
Susceptible Susceptible Dose Dependent(SDD) Resistant 
≥ 20mm 12-19 mm ≤ 11mm 
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IV   MASTER CHART 
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1 34 Female 
Vaginal 
swab 3 138 No 3 Pos 1 S S S 
         
- 
2 48 Female 
Vaginal 
swab 3 149 No 3 Pos 2 R S S Neg 
3 45 Female 
Vaginal 
swab 2,3 159 Yes 2 Pos 2 S S S 
         
- 
4 45 Female 
Vaginal 
swab 3 148 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
5 42 Female 
Vaginal 
swab 3 153 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
6 35 Female 
Vaginal 
swab 3 142 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
7 42 Female 
Vaginal 
swab 3,4 168 No 2 Pos 4 SDD S S 
         
- 
8 40 Female 
Vaginal 
swab 2 148 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
9 57 Female 
Vaginal 
swab 3 157 Yes 1 Pos 3 S S S 
         
- 
10 55 Female 
Vaginal 
swab 3 177 Yes 2 Pos 1 S S S 
         
- 
11 44 Female 
Vaginal 
swab 2,3 145 No 2 Pos 1 SDD S S 
         
- 
12 55 Female 
Vaginal 
swab 3 148 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
13 41 Female 
Vaginal 
swab 3 158 No 2 Pos 1 R S S Neg 
14 37 Female 
Vaginal 
swab 3 161 No 2 Pos 5 IR SDD S 
         
- 
15 40 Female 
Vaginal 
swab 2 138 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
16 33 Female 
Vaginal 
swab 2,3 142 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
17 62 Female 
Vaginal 
swab 3,4 167 No 1 Pos 2 R S S Pos 
18 53 Female 
Vaginal 
swab 2 146 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
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19 39 Female 
Vaginal 
swab 2 148 No 3 Pos 2 SDD S S 
         
- 
20 47 Female 
Vaginal 
swab 2 164 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
21 63 Female 
Vaginal 
swab 3 155 Yes 2 Pos 4 SDD S S 
         
- 
22 41 Female 
Vaginal 
swab 3 147 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
23 48 Female 
Vaginal 
swab 2 148 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
24 49 Female 
Vaginal 
swab 2 154 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
25 44 Female 
Vaginal 
swab 3 146 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
26 38 Female 
Vaginal 
swab 3 138 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
27 36 Female 
Vaginal 
swab 2,3 141 No 3 Pos 1 S S S 
         
- 
28 45 Female 
Vaginal 
swab 2 152 No 2 Pos 4 SDD S S 
         
- 
29 59 Female 
Vaginal 
swab 2,4 147 Yes 2 Pos 3 SDD S S 
         
- 
30 55 Female 
Vaginal 
swab 2,3 161 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
31 42 Female 
Vaginal 
swab 3 139 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
32 50 Female 
Vaginal 
swab 3 153 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
33 49 Female 
Vaginal 
swab 2 168 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
34 40 Female 
Vaginal 
swab 2 135 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
35 35 Female 
Vaginal 
swab 3 137 No 3 Pos 1 S S S 
         
- 
36 40 Female 
Vaginal 
swab 2 143 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
37 43 Female 
Vaginal 
swab 2,3 146 No 3 Pos 2 R S S Neg 
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38 48 Female 
Vaginal 
swab 3 153 No 2 Pos 4 SDD S S 
         
- 
39 36 Female 
Vaginal 
swab 3 135 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
40 44 Female 
Vaginal 
swab 3 157 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
41 39 Female 
Vaginal 
swab 3 140 No 2 Pos 2 S S S 
         
- 
42 44 Female 
Vaginal 
swab 3 136 No 2 Pos 1 S S S 
         
- 
43 61 Female 
Vaginal 
swab 3 165 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
44 69 Female 
Vaginal 
swab 2,3 171 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
45 42 Female 
Vaginal 
swab 2,3 158 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
46 55 Female 
Vaginal 
swab 2,3 163 No 1 Pos 1 SDD S S 
         
- 
47 65 Female 
Vaginal 
swab 2 157 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
48 55 Female 
Vaginal 
swab 2 153 No 3 Pos 5 IR S S 
         
- 
49 53 Female 
Vaginal 
swab 3 163 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
50 63 Female 
Vaginal 
swab 2,3 160 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
51 41 Female 
Vaginal 
swab 2 149 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
52 60 Female 
Vaginal 
swab 2 173 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
53 57 Female 
Vaginal 
swab 2 164 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
54 38 Female 
Vaginal 
swab 3 138 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
55 50 Female 
Vaginal 
swab 2 156 No 3 Pos 1 S S S 
         
- 
56 43 Female 
Vaginal 
swab 2 146 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
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57 40 Male Urine 1 154 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
58 40 Male Urine 1 146 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
59 57 Male Urine 1,5 181 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
60 48 Male Urine 1 169 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
61 45 Male Urine 1 152 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
62 48 Male Urine 1 161 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
63 75 Male Urine 5 182 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
64 62 Male Urine 5 179 Yes 1 Pos 1 S S S 
         
- 
65 70 Male Urine 5 165 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
66 58 Male Urine 1 153 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
67 78 Male Urine 1,5 165 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
68 61 Male Urine 1 172 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
69 59 Male Urine 1 151 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
70 56 Male Urine 1 147 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
71 62 Male Urine 1 166 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
72 72 Male Urine 5 186 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
73 70 Male Urine 1,5 173 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
  74 68 Male Urine 5 167 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
75 63 Male Urine 1 149 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
124 
 
S
.N
o
 
A
G
E
 
S
E
X
 
S
P
E
C
IM
E
N
 
S
Y
M
P
T
O
M
S
*
 
F
B
S
 (
m
g
/d
l)
 
O
N
 T
R
E
A
T
M
E
N
T
 
G
R
A
M
 S
T
A
IN
*
*
 
C
U
L
T
U
R
E
 
S
P
E
C
IE
S
*
*
*
 
F
L
U
C
O
N
A
Z
O
L
E
 
V
O
R
IC
O
N
A
Z
O
L
E
 
IT
R
A
C
O
N
A
Z
O
L
E
 
E
R
G
1
1
 P
C
R
 
76 61 Male Urine 1 163 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
77 55 Male Urine 5 152 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
78 60 Male Urine 1 145 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
79 58 Male Urine 1 147 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
80 72 Male Urine 5 168 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
81 75 Male Urine 5 153 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
82 76 Male Urine 1,5 161 Yes 2 Pos 4 SDD S S 
         
- 
83 55 Male Urine 1 157 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
84 75 Male Urine 5 163 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
85 60 Male Urine 1 149 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
86 63 Male Urine 1 165 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
87 50 Male Urine 1 156 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
88 55 Male Urine 1 163 Yes 3 Pos 1 S S S 
         
- 
89 73 Male Urine 1,5 169 No 1 Pos 3 S S S 
         
- 
90 75 Male Urine 1 161 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
91 65 Male Urine 1 154 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
92 72 Male Urine 5 174 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
93 60 Male Urine 1 168 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
94 59 Male Urine 1 176 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
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95 60 Male Urine 1 168 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
96 68 Male Urine 5 161 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
97 54 Male Urine 1 164 No 3 Pos 2 S S S 
         
- 
98 52 Male Urine 1 156 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
99 75 Male Urine 1 165 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
100 78 Male Urine 1,5 171 Yes 2 Pos 4 SDD S S 
         
- 
101 50 Male Urine 1 169 Yes 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
102 55 Male Urine 1 0 No 3 Neg 
          
- 
          
- 
          
- 
          
- 
         
- 
 
 
*Symptoms: Dysuria -1, Pruritis & Burning Sensation -2, Vaginal Discharge -3, Recurrence of 
Symptoms-4, Frequency And Urgency -5 
**Gram Stain: Budding Yeast Cells And Pseudohyphae -1, Budding Yeast Cells Only -2, 
Negative-3 
***Species: Candida albicans -1, Candida tropiclais -2, Candida parapsilosis-3, Candida 
glabrata-4, Candida krusei -5 
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V.  COLOUR PLATES 
 
Figure 1: Growth of different species of Candida on CHROM agar 
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Figure 2: Positive Germ tube test  
 
 
 
 
 
Figure 3: Morphology of Candida tropicalis on Corn meal agar 
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Figure 4: Morphology of Candida glabrata on Corn meal agar 
 
 
 
 
Figure 5: Sugar assimilation pattern of Candida albicans 
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Figure 6:  Fluconazole sensitive isolate on Mueller-Hinton Agar with 2% Glucose and        
0.5 μg/mL Methylene Blue Dye (GMB) Medium 
 
 
 
Figure 7:  Fluconazole resistant isolate on Mueller-Hinton Agar with 2% Glucose and        
0.5 μg/mL Methylene Blue Dye (GMB) Medium 
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Figure 8: ERG PCR: DNA Ladder- 1 -2 -3 (Negative isolates) – 4 (Positive isolate)-Negative 
control 
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                                                        VI- ABBREVIATIONS 
 
ATCC - American Type Culture Collection 
 
CLSI – Clinical Laboratory Standards Institute 
DNA - Deoxyribonucleic Acid 
DM – Diabetes mellitus 
ERG - Ergosterol 
GMB – Glucose with Methylene Blue  
IR – Intrinsic Resistance 
MHA - Mueller Hinton Agar 
MIC - Minimum Inhibitory Concentration 
NAC- Non-albicans Candida 
NCCLS – The National Committee for Clinical Laboratory Standards 
PCR – Polymerase Chain Reaction 
SDA – Sabouraud’s Dextrose Agar 
SDD - Susceptible Dose Dependent 
VVC- Vulvovaginal candidiasis 
YNB- Yeast Nitrogen Base 
 
